Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR

100% positive feedbacks

Martin Signer

Managing Director at 4Finance
Organizations: 4Finance
Languages: English, German, French, Spanish

278 connections

Notes

Relationship history

  • Reminders

    No reminders

  • Notes

    No notes

  • Convesations with Martin Signer

    No messages

  • Add to network

Martin Signer's personal:

Profile summary

Martin Signer holds a Masters degree (lic. oec. publ.) in quantitative finance from the economic faculty of the University of Zurich. Prior to his activity and founding 4Finance, he was responsible for the market risk management of the Clariden Bank. Besides his activity with 4Finance Martin Signer is also active as a university lecturer and author of several publications. Martin Signer was born in Zug. His hobbies are sports (tennis, and golf), chess and music.

Show more

Recent Activities

Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR

Martin Signer

3 days ago

Onda Group to Benefit from Eco-Bonus provided by Italian State

Onda Group to Benefit from Eco-Bonus provided by Italian State; Potential Market for Onda Group 1.200.000.000 (1,2 Billion)

 
 
 

Energy Company Benefiting from Anticipated Human Flight to Mediterranean Regions by Northern Europeans.

Onda Group, a preeminent supplier of energy to Southern Italian businesses, homes, and local utilities announces that it is ready to supply cheaper energy for restarting the economic engine of the region by supplying lower-cost energy alternatives for its customers. With the sharp drop in oil & gas prices and the huge disruption of the Italian economy, Onda plans to supply the region with cheaper energy alternatives that have not been seen in prices for the last 30 years. 
 
Cheaper energy means that the regions of Sicily, Sardegna, and the Southern Italian mainland should see a resurgence of economic activity partly due to lower energy costs provided by Onda. Onda will bring to the market a technological “Killer Application” able to collect new clients and keep them forever. A smart meter provides the consumption in €, of a single device (lamps, fridges, ovens, etc). Its name is Efficento, and it is a unique technology in the European market.

As Italy recovers from the Covid-19 pandemic, Onda is poised to help jump-start this economy by providing low-cost energy products to its customer base, and the company plans to rapidly expand and increase its market share in this region. The company CEO, Luigi Martines, states “Onda will make all efforts to sell its customers energy at low prices in order to get the Italian economy moving again. It is our responsibility as energy suppliers, to pass savings on to our customers for a quick and sustainable recovery. We expect to increase overall sales and expand our services in Sicily, Sardegna, and Southern Italy to make Onda a decisive player in the energy markets in the near future.”

Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR

Martin Signer

10 days ago

Todos Medical Announces First Commercial Sale of COVID-19 Antibody Tests

 
 
 

Todos Medical Announces First Commercial Sale of COVID-19 Antibody Tests

  •  Sub-distributor has a network of state and local government clients seeking testing solutions
  •  Return to Church program being initiated in Orlando, Fla. area

Todos Medical Ltd. (OTCQB: TOMDF), an in vitro diagnostics company focused on the distribution of a comprehensive suite of solutions for the screening and diagnosis of COVID-19 and the development of blood tests for the early detection of cancer and Alzheimer’s disease, today announced its first commercial sale of COVID-19 tests.  The sale was made via a sub-distribution agreement with a U.S.-based medical distribution company with clients in state and local governments throughout the Southeastern United States who are seeking comprehensive testing solutions for Return-to-Work programs. Todos’ sub-distributor’s first sale was for rapid IgM/IgG fingerprick antibody test kits that will be deployed over Memorial Day weekend for the first of several Return to Church programs being planned. Todos’ sub-distributor’s church network covers over 84,000 Christian church congregations reaching over 28 million Americans. 

“This sub-distribution agreement gives Todos’ U.S. distribution division access to a network of state and local governments, as well as Christian churches, and other communities of faith, that are for the first time pursuing COVID-19 testing services as they seek to responsibly reopen their congregations,” said Gerald E. Commissiong, President & CEO of Todos Medical. “We provide organizations and their lab partners with access to a comprehensive, steady supply of bundled, high-quality, FDA-compliant PCR, and antibody testing solutions that address their needs as they implement COVID-19 testing programs. As private organizations begin to take control of their COVID-19 testing, Todos plans to be a solutions provider for both organizations and labs seeking to more efficiently administer COVID testing in the United States.”

 
 
 
 

About Todos Medical Ltd.

Headquartered in Rehovot, Israel, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers. The Company's state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that deploys deep examination into cancer's influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Todos' two internally-developed cancer-screening tests, TMB-1 and TMB-2, have received a CE mark in Europe and are currently in a pre-commercial study with its distribution partner Orot+ (a division of Luces-Orot). Todos recently entered into an exclusive option agreement to acquire U.S.-based medical diagnostics company Provista Diagnostics, Inc. to gain rights to its Alpharetta, Georgia-based CLIA/CAP certified lab and Provista's proprietary commercial-stage Videssa® breast cancer blood test. The transaction is expected to close in the second quarter of 2020.

Through Breakthrough Diagnostics, Inc., its joint venture with Amarantus Bioscience Holdings, Inc. (OTC: AMBS), Todos is also actively involved with the development of blood tests for the early detection of neurodegenerative disorders, such as Alzheimer's disease. Todos expected to complete the remaining unowned interest in Breakthrough in the second quarter of 2020.

Todos recently entered into distribution agreements with China-based companies to distribute certain novel coronavirus (COVID-19) test kits. The Company has entered into distribution agreements covering the U.S. and Israel with Gibraltar Brothers & Associates, LLC, a U.S.-based subsidiary of Shanghai Liangrun Biomedicine Technology Co. (Shanghai), for its proprietary colloidal gold immunochromatography (Colloidal Gold) point-of-care IgM/IgM-based antibody test kits, and with 3DMedicine Science & Technology Co (3DMed), a China-based cancer precision medicine company, for distribution in the U.S. and Israel of its ANDiS® SARS-CoV-2 Detection Kit (COVID), ANDiS® SARS-CoV-2  & Influenza A/B Detection Kit (COVID/Flu) and its proprietary ANDiS®350 3DMed Automated Solution countertop real-time PCR machine (3D Machine). Todos has formed Corona Diagnostics, LLC, a joint venture with Emerald Organic Products, Inc.  (OTC: EMOR), to support the commercialization of its COVID-19 testing paradigm.


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR

Martin Signer

10 days ago

Omnia Wellness Is Prepared for Re-Opening of the Economy

Omnia Wellness ramps up its marketing activity as Medical Centers, Fitness Clubs, Corporate Offices, Salons, and Spas reopen in the US

 
 
 

Omnia Wellness is commercializing a new and innovative massage therapy approach with a unique automated massage bed called SolaJet that requires no personnel or a massage therapist. More than massage, SolaJet’s Dry-Hydrotherapy technology provides deep tissue suppression, therapeutic heat and a flushing full-body “wave” combining 3 therapies in 1. Treatments deliver the similar feeling of an hour-long traditional massage in as little as 15 minutes at an affordable price point for the consumer without the need of human hands.  Omnia Wellness is redefining and expanding the $45 billion global massage industry by delivering better, more efficient and a more customer-friendly massage experience.

Please find attached the Omnia Executive Summary and an Evergreen Research brief on Omnia Wellness, which describes the company’s target market, the SolaJet massage bed function and its benefits, and projected revenues. 

  • The SolaJet Dry-Hydrotherapy System is a massage bed that comprises a water-filled vessel where a powerful motor delivers all the benefits of conventional touch massage by pumping highly pressurized jets of water into specific parts of the impermeable barrier on a targeted basis
  • SolaJet’s hardware features are a strong water-proof flexible shell, a 4 horsepower motor and high pressure water jets which dispense from a rail mounted feeder that travels the full length of the body
  • SolaJet delivers a therapeutic massage through its flushing wave action and has heat therapy controls for the end-customer’s treatment requirements giving deep tissue massage, vibration, heat therapy and a full body flushing wave
  • SolaJet is operated through a touch screen tablet mounted to the side of the bed or user-determined smartphone app, so there is no need for human interaction with either a consultation with or touch from a designated on-premise practitioner

On April 21, 2020,  Omnia Wellness, Inc., trading under (OTC: OMWS), announced the entering into a Share Exchange and Reorganization Agreement with a Denver-based privately held company Bed Therapies, Inc. (now Omnia Wellness Corporation), pursuant to the Exchange Agreement 8K below.  The completion of the Exchange Agreement is expected by the end of June.


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR

Martin Signer

11 days ago

Baustaatssekretärin Bohle übernimmt Schirmherrschaft für den Sonderpreis Bezahlbares Bauen

„Nachhaltig, innovativ und zugleich bezahlbar bauen: Angesichts der politischen Rahmenbedingungen stehen Projektentwickler heute vor der Quadratur des Kreises. Zusätzlich erschweren die Folgen der Corona-Pandemie die Fertigstellung von neuen Projekten. Deshalb freuen wir uns sehr, dass Anne Katrin Bohle, Staatssekretärin im Bundesministerium des Innern, für Bau und Heimat die Schirmherrschaft für den „FIABCI/BFW Sonderpreis für bezahlbares Bauen“ übernommen hat!” Das gab Andreas Ibel, BFW-Präsident und Mitglied der Jury, heute in Berlin bekannt.

„Der von FIABCI und dem BFW ausgelobte Prix d’ Excellence Germany zeichnet herausragende Projekte aus, die vorbildhaft verschiedenste Ansprüche an moderne und nachhaltige Gebäude vereinen“, honoriert Anne Katrin Bohle, Staatssekretärin im Bundesbauministerium. „Gerade in Zeiten der Corona-Pandemie zeigt sich die mittelständische Immobilienwirtschaft als ein starkes Rückgrat in der Wertschöpfungskette der Bundesrepublik. Gerne übernehme ich daher erneut die Schirmherrschaft für den „Sonderpreis für bezahlbares Bauen“ und freue mich auf zahlreiche Projekte die zur Nachahmung anregen.“

„Neben der Bezahlbarkeit sind innovatives Denken und Bauen eine der größten Herausforderungen für Projektentwickler“, sagt Michael Heming, Präsident FIABCI Deutschland. „Deshalb loben wir einen weiteren Preis, den Innovationspreis aus: Denn wir wollen zu innovativem nachhaltigem Bauen inspirieren und die Synergien zwischen Bauwirtschaft und Baukultur fördern!“

Zum ersten Mal in der Geschichte des FIABCI Prix d´ Excellence Germany wird der Sonderpreis „Langer Atem“ ausgelobt – „mit einem Augenzwinkern“, so Heming und Ibel: „Allen Projektentwicklern ist gemein, dass sie mit Abstimmungsproblemen, langwierigen Prozessen und baurechtlichen Hindernissen zu kämpfen haben. Deshalb vergeben wir den Preis für den Projektentwickler, der mit den skurrilsten Problemen zu kämpfen hatte, um sein Projekt fertig zu stellen!“

Für den FIABCI Prix d´Excellence Germany 2020 sind alle Immobilienprojekte zugelassen, deren Fertigstellung zwischen dem 1. Januar 2018 und 31. Dezember 2020 erfolgt ist. Die Bewerbungen können bis zum 15. Juni eingereicht werden. Die Gewinner des Wettbewerbs werden am 13. November im Rahmen einer feierlichen Gala im Berliner ewerk gekürt.


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR

Martin Signer

11 days ago

Subsidiary of the Solution of ViralClear to Treat Adult Patients with Advanced COVID-19

FDA Clears the Investigational New Drug Application to Enable the Phase II Trial of ViralClear’s Merimepodib, Oral Solution to Treat Adult Patients with Advanced COVID-19

 

Todos Medical Ltd. (TOMDF), a pre-commercial stage in vitrodiagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, announces that its President and Chief Executive Officer Gerald E. Commissiong has provided the following corporate update on the Company’s ongoing initiatives, including progress with its novel coronavirus (COVID-19) joint venture Corona Diagnostics, LLC,   the ongoing breast cancer commercialization trial with its proprietary blood spectroscopy platform, and the pending acquisition of its Alzheimer’s disease joint venture Breakthrough Diagnostics, Inc.

 

 

  • Phase II clinical trial expected to be conducted at multiple centers in the United States, including three Mayo Clinic sites under the leadership of Andrew D. Badley, M.D., Enterprise Chair of COVID-19 Task Force
  • A randomized, double-blind, placebo-controlled clinical trial to be conducted in adults with COVID-19 who are hospitalized and either require supplemental oxygen or are on non-invasive ventilation or high flow oxygen devices

 BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) and its majority-owned subsidiary, ViralClear Pharmaceuticals, Inc. (ViralClear), today announced that the U.S. Food and Drug Administration (FDA) has completed its review of ViralClear’s Investigational New Drug (IND) application. The FDA informed ViralClear that it may proceed with a proposed phase II study of merimepodib oral solution in adults with COVID-19 who are hospitalized and either require supplemental oxygen or are on non-invasive ventilation or high flow oxygen devices.

This study will be a randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of merimepodib as an orally administered treatment. The trial will occur in hospitalized patients who have confirmed infection with SARS-CoV-2 and require supplemental oxygen.

“I’m very pleased to be involved in this planned Phase II study of merimepodib for the treatment of patients with COVID-19 disease,” said Andrew D. Badley, M.D., Professor and Chair of Department of Molecular Medicine and the Enterprise Chair of COVID-19 Task Force. “We are grateful to the FDA for their prompt response in helping accelerate opportunities to find treatments for the novel coronavirus. We plan to begin enrollment of this trial as soon as practicable given the importance of finding solutions to this pandemic.”

“FDA clearance for our proposed phase II trial to proceed is an important step for the development of merimepodib,” commented Jerome B. Zeldis, M.D., Ph.D, Executive Chair, co-founder and acting Chief Medical Officer of ViralClear Pharmaceuticals, Inc. “We intend to conduct Phase II evaluations of our drug both in the hospital and outpatient settings as part of our clinical development plan.”

“We thank the Mayo Clinic for collaborating with us to conduct the trials under the leadership of Professor Badley,” said Nick Spring, Chief Executive Officer of ViralClear Pharmaceuticals, Inc. “Of the therapies that are currently being evaluated as treatments and can be available in the short term, we believe that a broad-spectrum antiviral that is orally administered and widely available could be very helpful in addressing the COVID-19 pandemic. We further believe it can play a pivotal role in helping manage this type of public health crisis.”

 

About BioSig Technologies
BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals (www.biosig.com).

The Company’s first product, PURE EP(tm) System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring, and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.

About Merimepodib (MMPD)
Merimepodib, a broad-spectrum anti-viral candidate, that demonstrates strong activity against COVID-19 in cell cultures in laboratory testing and additional antiviral studies are underway.  Merimepodib was previously in development as a treatment for chronic hepatitis C and psoriasis by Vertex Pharmaceuticals Incorporated (Vertex), with 12 clinical trials conducted (including 315 chronic hepatitis C patients, 24 psoriasis patients, and 98 healthy volunteers) and an extensive preclinical safety package completed.

A manuscript titled, “The IMPDH inhibitor merimepodib provided in combination with the adenosine analog remdesivir reduces SARS-CoV-2 replication to undetectable levels in vitro”, was submitted to an online peer-reviewed life sciences journal. This manuscript is authored by Natalya Bukreyeva, Rachel A. Sattler, Emily K. Mantlo, John T. Manning, Cheng Huang, and Slobodan Paessler of the UTMB Galveston National Laboratory and Dr. Jerome Zeldis of ViralClear Pharmaceuticals, Inc. (“ViralClear”) as a corresponding author. This article highlights pre-clinical data generated under contract with Galveston National Laboratory at The University of Texas Medical Branch.

About ViralClear
BioSig’s subsidiary ViralClear Pharmaceuticals, Inc., is seeking to develop a novel pharmaceutical to treat COVID-19. Merimepodib is intended to be orally administered and has demonstrated broad-spectrum in vitro antiviral activity, including strong activity against COVID-19 in cell cultures. Merimepodib has been previously studied in 12 clinical trials, including 5 in patients with hepatitis C (1 Phase 1b, 1 Phase 2, 2 Phase 2a, and 1 Phase 2b), 1 in patients with psoriasis (Phase 2), and six in healthy volunteers (Phase I). 


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR

Martin Signer

13 days ago

Reckless arms exporters to Saudi Arabia worst hit by COVID-19

Reckless arms exporters like the US and the UK - big arms exporters to Saudi Arabia - are among the worst-hit countries from COVID-19. Is this a surprise?

Infographic: Who Exports Arms to Saudi Arabia? | StatistaAs visible, these are almost the same countries that are proportionally hardest-hit with COVID-19

Infographic: The World's Largest Arms Suppliers | Statista 

No.

As already mentioned earlier, arms exports are usually done with barter trades and they are typically aligned with - at least morally - corrupt governments that don't value the well-being of others.

As an example, the defense minister of Switzerland - a country with huge war material exports - only concentrated on the barter agreement for a new military airplane instead of pandemic prevention. This lead - among other reasons - to Switzerland becoming one of the worst-hit countries from COVID-19.

 


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR

Martin Signer

14 days ago

Wo verliert man gute Lebensjahre?

Article about Wo verliert man gute Lebensjahre?


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR

Martin Signer

14 days ago

By looking at the data it would make sense to tax beef and lamb meet more instead of VAT

 


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR

Martin Signer

14 days ago

Umweltpolitik mit höherer Besteuerung von Rinds- und Lammfleisch und tieferer Mehrwertsteuer

Article about Umweltpolitik mit höherer Besteuerung von Rinds- und Lammfleisch und tieferer Mehrwertsteuer

Rind- und Lammfleisch sind die Proteinquellen, welche am meisten Treibhausgase emittieren und sollten daher höher besteuert werden (dafür sollte die asoziale Mehrwertsteuer reduziert/abgeschafft werden).

 


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR

Martin Signer

17 days ago

Merimepodib and Remdesivir Against SARS-CoV-2

ViralClear Publishes in F1000 Research In Vitro Data Demonstrating Synergy between Merimepodib and Remdesivir Against SARS-CoV-2, the Cause of COVID-19

 
 

Todos Medical Ltd. (TOMDF), a pre-commercial stage in vitrodiagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, announces that its President and Chief Executive Officer Gerald E. Commissiong has provided the following corporate update on the Company’s ongoing initiatives, including progress with its novel coronavirus (COVID-19) joint venture Corona Diagnostics, LLC,   the ongoing breast cancer commercialization trial with its proprietary blood spectroscopy platform, and the pending acquisition of its Alzheimer’s disease joint venture Breakthrough Diagnostics.

 

Westport, CT, May 14, 2020 (GLOBE NEWSWIRE) --

  • Merimepodib in combination with remdesivir decreases viral production of SARS-CoV-2 to undetectable levels in pre-clinical testing.  Even at low concentrations of both drugs significant reduction in viral production occurs.
  • Article highlights recent work done in laboratory studies of COVID-19 with merimepodib at the Galveston National Laboratory at The University of Texas Medical Branch

BioSig Technologies, Inc. (Nasdaq: BSGM) today announced that an article titled, The IMPDH inhibitor merimepodib provided in combination with the adenosine analog remdesivir reduces SARS-CoV-2 replication to undetectable levels in vitro” was published by F1000 Research, an online peer-reviewed life sciences journal publishing program in biology and medicine, while it is undergoing peer review.

This manuscript is authored by Natalya Bukreyeva, Rachel A. Sattler, Emily K. Mantlo, Timothy Wanninger, John T. Manning, Cheng Huang, and Slobodan Paessler of the UTMB Galveston National Laboratory and Dr. Jerome Zeldis of ViralClear Pharmaceuticals, Inc. (“ViralClear”) as a corresponding author. The link to the manuscript is https://f1000research.com/articles/9-361/v1.

The article highlights pre-clinical data generated under contract with Galveston National Laboratory at The University of Texas Medical Branch. 

“The results of these laboratory investigations have strongly influenced our plans for the initial clinical trials of merimepodib. We have experimental evidence that merimepodib is active as monotherapy and in combination with remdesivir,” commented Jerome Zeldis, M.D., Ph.D.,  Executive Chair and Co-Founder of ViralClear Pharmaceuticals, Inc. “Our first proposed COVID-19 trial is expected to be conducted in hospitalized patients who require supplemental oxygen and receive remdesivir as part of their standard of care.  Patients will be randomized to either placebo or merimepodib. In this manner, the potential synergy between merimepodib and remdesivir may be evaluated in the clinical setting.  An additional trial in the outpatient setting with just merimepodib is proposed to follow the initiation of the first trial.”

About BioSig Technologies
BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals (www.biosig.com).

The Company’s first product, PURE EP(tm) System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring, and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.

About ViralClear
BioSig’s subsidiary ViralClear Pharmaceuticals, Inc., is seeking to develop a novel pharmaceutical to treat advanced COVID-19.

Merimepodib is a broad-spectrum antiviral agent that has demonstrated strong activity against the SARS-CoV-2 virus in cell cultures in laboratory testing. ViralClear plans to initiate a multi-center, phase 2, randomized, double-blind, placebo-controlled study of the efficacy and safety of merimepodib administered orally three times a day for 10 days in combination with remdesivir administered by intravenous infusion once a day for 5 or up to 10 days in adult patients with advanced COVID-19 upon FDA clearance to proceed. Merimepodib has been studied in twelve clinical trials prior to this planned study, including five trials in patients with hepatitis C (one phase 1b, one phase 2, two-phase 2a, and one phase 2b), one trial in patients with psoriasis (phase 2), and seven trials in healthy volunteers (phase 1). 

Remdesivir is an adenosine analog that displays broad-spectrum antiviral activity against RNA viruses and has been developed by Gilead Pharmaceuticals for the treatment of Ebola. On May 1, 2020, remdesivir received an FDA Emergency Use Authorization to treat COVID-19 in adults and children hospitalized with severe disease.


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR

Martin Signer

17 days ago

Bauträger zunehmend von Folgen der Corona-Pandemie betroffen

„Die Auswirkungen der Corona-Pandemie stellen die mittelständische Immobilienwirtschaft vor immer größere Herausforderungen. Unsere neue Mitgliederumfrage zeigt: Neben den Bestandshaltern sind nun auch die Bauträger zunehmend betroffen“, sagte Andreas Ibel, Präsident des BFW Bun-desverbandes Freier Immobilien- und Wohnungsunternehmen, heute in Berlin. Hier präsentierte Ibel die neue Umfrage unter den mittelständischen BFW-Mitgliedsunternehmen, die 50 Prozent der Wohnungs- und 30 Prozent der Gewerbeimmobilien bauen und 14 Prozent des gesamten Mietwoh-nungsbestandes verwalten.

In der Umfrage geben 75 Prozent der befragten Immobilienunternehmen an, dass ihr Geschäftsbetrieb durch die Corona-Krise beeinträchtigt ist. Dabei rechnen 65 Prozent der Bestandshalter mit Beeinträchtigungen. Bei den Bauträgern und Projektentwicklern sind es sogar 79 Prozent.

Auswirkungen auf der Baustelle

Die größten Probleme für die Bauträger sind neben der Vermarktung (38 Prozent) die Planung und Genehmigung neuer Projekte (37 Prozent). So berichten vier Fünftel der Bauträger, dass die Erteilung von Baugenehmigungen, die Schaffung von Planungsrecht und die Bauleitplanung auf kommunaler Ebene noch länger dauern als ohnehin üblich. Auch beim Betrieb und der Organisation von Baustellen kommt es laut 21 Prozent zu Schwierigkeiten, etwa durch das Ausbleiben von Subunternehmen oder durch die erforderlichen Sicherheitsmaßnahmen. Darüber hinaus berichten 38 Prozent der Bauträger von verzögerten oder unterbrochenen Lieferketten.

Drei Viertel der Bauträger rechnen mit Umsatzeinbußen

Entsprechend verhalten äußern sich die Bauträger beim Blick in die Zukunft: So gehen 61 Prozent davon aus, dass die Anzahl der beantragten Baugenehmigungen in diesem Jahr sinken wird. 71 Prozent der Befragten rechnen damit, dass sich geplante Baubeginne um mehrere Monate verschieben werden. Für 63 Prozent zeichnet sich schon jetzt ab, dass es auch bei der Fertigstellung von Projekten zu mehrmonatigen Verzögerungen kommen wird. Die Folge: Drei Viertel der Bauträger rechnen damit, dass sich die Pandemie negativ auf ihren Umsatz auswirken wird. 28 Prozent geben an, dass ihr Umsatz voraussichtlich um mehr als zwanzig Prozent zurück gehen wird. Dennoch nehmen bislang nur 13 Prozent der befragten Unternehmen staatliche Hilfen in Anspruch. Lediglich 17 Prozent schicken Mitarbeitende in Kurzarbeit.

Jetzt sind die Kommunen gefragt!

„Die Immobilienunternehmen spielt eine Schlüsselrolle, wenn es darum geht, unsere Wirtschaft nach dem Lock-Down wieder anzukurbeln. Auch das Problem der Wohnungsknappheit wird sich weiter verschärfen, wenn wir hier nicht gegensteuern“, sagte Ibel und erklärte: „Als Mittelstand haben wir bislang staatliche Hilfen für unsere Kunden und Mieter, nicht aber für unsere Unternehmen gefordert. Deshalb ist es jetzt dringlicher, dass Verfahren auf kommunaler Ebene weiter vereinfacht, beschleunigt und digitalisiert werden, um einen Einbruch beim Neubau abzuwenden. Mit dem Planungsbeschleuni-gungsgesetz hat der Bund hierfür die Rahmenbedingungen neu justiert. Jetzt sind die Kommunen gefragt!“

Die Umfrage wurde vom 29. April bis zum 6. Mai erhoben. Die detaillierten Umfrageergebnisse können Sie hier einsehen.


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR

Martin Signer

18 days ago

Zapaygo: The contactless payment platform

 

 
 

Imagine being able to order your food and drinks as you are approaching a venue, not waiting in lines to order, pay and have your order prepared. Everything is just there ready for you to collect. Ordering from your seat and not having to try and get a server’s attention or leave people and stand at a bar waiting while you miss that vital business discussion, joke or sporting moment! You don’t even have to wait for the bill when you’re finished. What’s more, you do not have to handle money, touch card machines or ATM’s, you don’t have to queue and/or stand in confined spaces waiting for your order to be prepared (all mitigating the risk of spreading disease). Not only do you save time and stay safe, but you also earn rewards and cashback.
You can do all this from a free, user-friendly app that allows you to pre-order from your favourite places.
Pre-order > Save Time > Earn Rewards
and “STAY SAFE”


What Zapaygo has:
  • Great contract with MSL Solutions to ensure millions of users are quickly onboarded, integrated into over 60% of the UK’s high profile Sports and Concert venues EPOS systems.
  • MVP ready to go.
  • Routes to tens of thousands of bars and pubs via senior teams contacts
  • Partnerships (signed or teed up) with Monek / Datam / Rimilia / Paycasso / Interactions / Rapyd / Global Reach / Push Technology / PayPal /Amex / Birmingham 2020 / VODXS/ Dubai World Expo 2021 / Tata Consultancy services blockchain rewards program / Rypplzz
  • Endless launch opportunities in the UK due to team contacts (too many to mention).
  • A perfect storm business opportunity now due to COVID-19, businesses need to reopen.
  • Great team with all the contacts and experience needed.
  • Zapaygo also has its own delivery software ready to roll out, www.zapaygodelivered.com
  • Lots of lessons learned and heavy lifting completed
  • See how it works 
  • There is also an IEO starting at 09:00 local time in Singapore on Sunday 17th May please visit www.wenxpro.com to sign up ready.
Invest
 
 



Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR

Martin Signer

19 days ago

FLUXUS introduces an AI-enabled Digital Toolkit for Affordable Housing Development

FluxHouse™ Generative, an AI-enabled Digital Toolkit for Affordable Housing Development

Fluxus is pleased to introduce FluxHouse™ Generative, a state-of-the-art AI-enabled digital toolkit for developers and governments to design, assess, and deploy affordable housing projects.

“While affordable housing delivery is increasingly impacted by the current situation with supply chain interruptions, construction slowdowns, and funding shortages, we are also witnessing the acceleration of digital transformation in construction and real estate sectors that are ripe for innovation for a long time. Embracing tools and platforms for digitalization will help developers and governments to better manage risk, enable collaborative workflow globally, plan for sustainability, and ultimately help to strengthen the ability of communities to meet the affordable housing needs.” – Fanyu Lin, CEO of Fluxus.

In FluxHouse™ Generative, algorithms are developed to automate the assembly of the FluxSystem’s 9 components to form varying massings and layouts which directly respond to define physical and environmental conditions. The tool adapts typical footprints, using GIS-data, to optimize volumes to achieve the highest yield of units and drive value. Customizable floor plans are spacious and aesthetic with liberal use of natural lighting. Passive design principles are incorporated with IoT solutions to reduce energy consumption.

Committed to offering an energy-efficient and affordable housing solution for quality of living through leveraging networks of global partners and digitalization of construction, Fluxus is looking forward to engaging with more government, developer, housing provider, funder and other interested parties to roll out development projects while creating industry-wide resilience in a post-Covid-19 world.

 

About Fluxus

Founded in 2013 in New York City, Fluxus LLC is a privately held construction/architecture technology company, committed to delivering affordable housing through a prefab building platform that leverages networks of global partners and innovations in smart city technologies, green building materials, intelligent design, industrialization and digitalization of construction.


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR

Martin Signer

20 days ago

How is smoking and COVID-19 related?

Article about How is smoking and COVID-19 related?

The WHO is not very clear in its statement.

There is a study running on whether nicotine patches might help.

Below also some data to compare.


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR

Martin Signer

25 days ago

ETF Stream aquires AltFi

 

According to a newsletter from AltFi, they are joining ETF Stream, as part of an expansion plan for both publications in Europe.

Over the last 18 months, AltFi has seen a huge growth in our readership along with an expansion of the events and research business.

The two brands will remain editorially independent and separate from each other but will benefit from expanded events, marketing, and sales team.

They aim to keep writing the cutting-edge fintech and alternative finance stories that matter to you, and covering the most exciting and original innovators in financial services and banking.


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR

Martin Signer

26 days ago

Genprex is 39%up on premarket on Oncoprex IP deal

  • Nano cap Genprex (NASDAQ:GNPX) jumps 39% premarket on robust volume in reaction to its agreement with MD Anderson Cancer Center for exclusive global rights to a portfolio of 16 patent applications and related technology for the treatment of cancer using TUSC2 gene therapy Oncoprex combined with other immunotherapies, including PD-1/L1 inhibitors, PDL2 inhibitors, anti-CTLA-4 antibodies and/or anti-KIR antibodies.
  • The company plans to file an IND for a clinical trial evaluating the combination of Oncoprex and Merck's (NYSE:MRK) Keytruda (pembrolizumab) in patients with non-small cell lung cancer.
  • It says this therapeutic approach is distinctly different from combining Oncoprex with targeted therapies like AstraZeneca's Tagrisso (osimertinib).

Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR

Martin Signer

27 days ago

The HSC Fund purchases a modern and profitable multi-tenant property close to Geneva airport

The Helvetica Swiss Commercial Fund (HSC Fund) acquires a modern, mixed-use commercial property in Versoix in the Canton of Geneva. The market value of the property amounts to CHF 31.14 million. The rental income from the property derives from 8 tenants and is largely secured over the next 10 years by the seller with a guarantee structure established over different levels.

 

The HSC Fund signed a purchase agreement for a modern, mixed-use commercial property in Versoix/GE with a privately held company. The property is situated in a well-developed and economically intensive location close to the airport Geneva. The property has a rentable surface of around 7,300 square meters and generates an income of ca. CHF 1.43 million per year with 8 tenants. The acquired property measures around 12,750 square meters.

The property is mostly rented out on a long-term basis. A large part of the rental income is collateralized for the long-term over a contractually protected transaction structure. This transaction structure ensures that the HSC Fund accrues the full target rental income regardless of the future occupancy rate. Of the contractually agreed rental income of around CHF 14.3 million over the next 10 years, over CHF 7.3 million are guaranteed by a combination of temporary retention of the purchasing price and additional ten-year bank guarantees. In addition to the usual tenant’s security deposits, the seller’s parent company secures all of the seller’s obligations over the duration of 10 years. The seller will also oversee the management of the building in the future.

The multi-tenant property at a very attractive location

The property was built in 2013. The average rent (excl. parking) amounts to around CHF 180 per square meter and year. In addition to the very attractive transaction structure, the HSC fund also benefits from the fact that it is only responsible for the maintenance of the constructive elements of the new property. All other investments, also investments in rental spaces, and all auxiliary costs are covered by the property manager. As such the actual return which lies just under 5% on the invested capital, is further improved be a very low “double-net cost structure”. The return on the market value lies at the time of purchase at around 4.6%.

Purchase agreement notarized, benefits and risks transferred retroactively as of 1 May 2020

The purchase agreement was notarized in Geneva on 30 April 2020 in compliance with the social distancing requirements of the Federal Council. In the Canton of Geneva, the contract is subject to a statutory right of first refusal by the FTI (Foundation pour les terrains Industriels). The contracting parties do not expect the FTI to exercise this right of first refusal. Subject to the FTI's right of first refusal, the transfer of benefits and risks will take place retroactively as of 1 May 2020.

"With the acquisition of this property and the transaction structure, we can ideally meet the current needs of our investors: Our investors not only benefit from an attractive return but also enjoy the greatest possible cash flow security due to the extensive rent guarantees deposited to secure the business as well as the staggered payment of the purchase price," says Frederic Königsegg, Chief Investment Officer.

HSC Fund expands its portfolio into the French-speaking part of Switzerland with this acquisition and continues its long-term growth strategy prudently and in the interest of its investors.


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR

Martin Signer

28 days ago

Novacyt mises à jour sur le test pour le coronavirus et date de publication des résultats

Novacyt (ALTERNEXT : ALNOV ; AIM : NCYT), spécialiste mondial du diagnostic clinique, fait le point sur son test d'amplification en chaîne par polymérase (PCR) pour le COVID-19 mis au point par Primerdesign, la division de diagnostic moléculaire du Groupe basée au Royaume-Uni.

Ventes

En date du 28 avril 2020, Primerdesign a vendu, reçu des commandes ou été sélectionné pour livrer pour plus de 90 millions de livres sterling (103 millions d'euros) de tests pour le COVID-19. Ce chiffre comprend le montant minimum de commandes de tests prévu par le contrat d'approvisionnement récemment signé avec le Ministère britannique de la Santé et des Affaires Sociales et la demande minimum prévue dans le cadre des collaborations avec AstraZeneca, GSK et l'université de Cambridge.

Novacyt fournit désormais son test COVID-19 dans plus de 100 pays et des approbations pour ce test ont été récemment reçues de la Malaisie et de l'Équateur. Le Groupe continue d’accroitre son niveau de vente sur le marché américain et évalue les options possibles pour étendre sa présence sur cet important marché.

Capacité de production

Le 15 avril 2020, Novacyt a annoncé une stratégie visant à augmenter la capacité de production à environ huit millions de tests par mois. Le Groupe est en bonne voie pour la réaliser et prévoit d'atteindre au moins ce niveau de production en juin 2020. En outre, Novacyt a signé des contrats de sous-traitance avec deux autres fabricants basés au Royaume-Uni. Novacyt dispose ainsi d'un total de six fabricants en sous-traitance en plus de ses propres sites de production à Southampton et à Camberley, ce qui lui permet de disposer d'une plus grande marge de manoeuvre et d'une plus grande flexibilité pour augmenter sa production au-delà de huit millions de tests par mois si nécessaire

Recherche et développement

Comme annoncé le 15 avril 2020, Novacyt s'est efforcé de remédier à la pénurie globale actuelle de réactifs d'extraction nécessaires pour réaliser les tests PCR en développant une nouvelle technologie d'extraction. Cette technologie permet d'éviter l'utilisation de billes magnétiques couramment utilisées dans ces réactifs d'extraction. Le développement d'une nouvelle méthode d'extraction « direct-to-PCR », Exsig™ Free, utilisée avant l'exécution du test COVID-19 du Groupe, supprimera ainsi le besoin de ces billes magnétiques utlisés dans ces réactifs en nombre limité et réduira considérablement le nombre d'étapes d'extraction, permettant des temps de cycle plus rapides, des débits plus élevés et des économies de coûts. La Direction du Groupe estime que cette innovation devrait faciliter l'augmentation de la capacité à réaliser les tests COVID-19, en supprimant pour les laboratoires le goulot d'étranglement actuel du traitement des échantillons. Le développement progresse et Novacyt est en bonne voie pour lancer cette nouvelle technologie d'extraction en mai 2020. Page 2 of 3

Nouvelle date de publication des résultats financiers 2019

Du fait d’une procédure de revue des états financiers rallongée à cause du COVID-19, le Groupe a l'intention de présenter ses résultats audités pour l'exercice clos le 31 décembre 2019 au cours de la semaine du 11 mai 2020.

Graham Mullis, Directeur général de Novacyt, commente :

« La visibilité du carnet de commandes va changer la dimension du Groupe et il devient de plus en plus évident que cette demande exceptionnelle pour notre test COVID-19 continuera pendant plusieurs mois. Par conséquent, nous continuons à nous assurer que nous disposons d'une capacité et d'une flexibilité suffisantes pour la production de notre test COVID-19.

Je suis fier que l'innovation reste au coeur de notre activité et le lancement prochain de notre kit d'extraction Exsig™ Free répondra à un besoin important du marché pour augmenter l’accès aux tests et la productivité pour les effectuer. C'est une période exigeante pour Novacyt, mais la transformation de nos performances financières et notre position de leader sur le marché des diagnostics cliniques nous rendent confiants dans les perspectives à long terme du Groupe. »


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR

Martin Signer

1 month ago

Aussichten und Zwischenbilanz zur COVID-19-Pandemie

Article about Aussichten und Zwischenbilanz zur COVID-19-Pandemie

Wie aktuelle Daten zeigen, haben Nordamerika und Europa besonders schlecht (d. h. verspätet) auf die COVID-19-Pandemie reagiert. Zudem ist die Interpretation der Daten auch nicht immer einfach.

Während der US Präsident Donald Trump - wie auch das BAG - viel zu spät reagiert haben und jetzt zu dümmsten Zeitpunkt während einer laufenden Pandemie der WHO die Mittel entzieht, wurden jedoch durch die WHO - 

Viele Wirtschaftszweige, wie bspw. der Sportbereich, haben riesen Einbussen.

Wie geht es weiter

  • Man kann aus Simulationen die Erkenntnis gewinnen, dass das Problem wohl noch lange nicht gelöst ist, sondern zumindest ein effektives Medikament benötigt wird, bis zu eine geeigneter Impfstoff gefunden wird. Dies wird wohl - trotz grossen Anstrengungen - wohl frühestens im Jahr 2021 für die breite Bevölkerung vorhanden sein. Bei einer möglichen Saisonalität wird somit spätestens das Winterhalbjahr 2020/2021 eine Herausforderung (bzw. für die Südhalbkugel der Winter 2020)

Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR

Martin Signer

1 month ago

Negative income tax for COVID-19 and later would make sense

Article about Negative income tax for COVID-19 and later would make sense

When we see the issues of social disparities - not only during the COVID-19 crisis - we should think about the negative income tax.

negative income tax, as Friedman saw it, would, therefore, solve two main problems: It would give people cash as opposed to in-kind benefits and have a much lower tax rate. While people would still lose benefits the more they made, with a negative income tax, they would always come out ahead with a higher income.

It doesn't solve all issues, but would be more efficient than the current system as this case study for Mongolia illustrates.


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR

Martin Signer

1 month ago

When will we be playing sports again in a normal fashion?

Article about When will we be playing sports again in a normal fashion?


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR

Martin Signer

1 month ago

Abgetrennte Velowege als möglicher Lichtblick nach COVID-19

Article about Abgetrennte Velowege als möglicher Lichtblick nach COVID-19

Zürich gilt als eine Stadt mit einer hohen Lebensqualität.

Allerdings gibt es einige Probleme wie:

 


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR

Martin Signer

1 month ago

Lernen wir von der COVID-19-Pandemie für die angesagten Umweltkatastrophen?

Article about Lernen wir von der COVID-19-Pandemie für die angesagten Umweltkatastrophen?

Bei der (vorangekündigten) COVID-19-Krise hatte man trotz klaren Indizien viel zu spät gehandelt.

Warnende (auch prominente) Stimmen hatten schon lange davor gewarnt

Es gab natürlich auch Personen, welche dies in Zweifel gezogen haben, bzw. nicht gehandelt.

 

Es ist unübersehbar, Parallelen zu der Umweltproblematik zu sehen

 

Es wäre wohl an der Zeit, vom "Locker room talk" bzgl. Klimakrise zu wirklichem Handeln überzugehen, bevor die Schäden auch (noch) offensichtlicher werden, auch wenn es etwas länger dauert und die Konsequenzen etwas länger dauern.

 


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR

Martin Signer

1 month ago

Novacit fait un contrat avec le Ministère de la Santé et des Affaires Sociales britannique pour la fourniture de tests COVID-19

Novacyt S.A.

(« Novacyt » ou la « Société »)

Contrat avec le Ministère de la Santé et des Affaires Sociales britannique pour la fourniture de tests COVID-19

Paris, France et Camberley, Royaume-Uni – 27 avril 2020 – Novacyt (ALTERNEXT : ALNOV ; AIM : NCYT), spécialiste mondial du diagnostic clinique, annonce avoir signé un contrat d’approvisionnement avec le Ministère de la Santé et des Affaires Sociales britannique (Department of Health and Social Care - DHSC) pour son test COVID-19 (CE IVD) d'amplification en chaîne par polymérase (PCR), développé par Primerdesign, la division de diagnostic moléculaire du Groupe basée au Royaume-Uni.

Selon les termes de l'accord, Novacyt fournira son test COVID-19 au DHSC pour une période initiale de six mois à compter du 4 mai 2020. Novacyt s'est initialement engagée à fournir 288 000 tests par semaine au DHSC pour une utilisation dans le cadre du National Health Service (NHS), avec la possibilité d'étendre l'accord.

Ce partenariat avec le DHSC renforce l’appui actuel de Novacyt au plan du Gouvernement britannique, qui repose sur cinq piliers, visant à augmenter le nombre de tests pour le COVID-19. Le contrat s'ajoute à la collaboration du Groupe annoncée le 8 avril 2020 avec AstraZeneca, GSK et l'Université de Cambridge dans le cadre de laquelle Novacyt s'engage à assurer un processus efficace pour depister le COVID-19, fournir son test COVID-19 et générer des données à partir des résultats.

Graham Mullis, Directeur général de Novacyt, commente :

« Novacyt s'est engagé à lutter contre la pandémie mondiale de COVID-19. Ce partenariat avec le Ministère de la Santé et des Affaires Sociales renforce la position de Novacyt comme principal fournisseur de tests COVID-19 pour le NHS. »


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR

Martin Signer

1 month ago

We should learn from Iceland

Also, almost some Asian countries reacted much better than countries in Europe and North America.


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR

Martin Signer

1 month ago

Neue Tattoos anstatt Masken

Article about Neue Tattoos anstatt Masken

Während man bspw. in der Schweiz entscheidende Massnahmen zur COVID-19-Eindämmung mindestens drei Wochen vertrödelt hat, ist man dafür umso schneller mit der Wiedereröffnung der Tattoostudios, Das ein neues Tattoo vielleicht nicht die höchste Priorität haben sollte, ist immerhin auch Bill Gates aufgefallen.

Die Behördenaussagen scheinen nicht sehr konsistent, bspw. wenn von Daniel Koch vom BAG immer noch behauptet wird, dass Masken eher kontraproduktiv sein sollen. Gesunder Menschenverständ wäre eine starke Waffe, die meisten sind jedoch unbewaffnet.

Aktuelle Daten zeigen kein gutes Bild.

Die Schweiz hält sich so konsistent unter den Ländern mit der höchsten COVID-19-Todesquote

 

Somit reiht sich die Schweiz unter die Staaten mit den inkompetentesten Regierungen ein.

Wie aus dem Aufsatz von Prof. Dr. med. Dr. h. c. Paul Robert Vogt hervorgeht, erstaunt dies für dies für die Schweiz auch nicht, wie bspw. auch andere Versäumnisse zeigen. 

Schweden scheint dabei zum Verwechseln ähnlich. Auch macht man eine Umverteilung von Unten nach Oben.

 

 


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR

Martin Signer

1 month ago

Ziemlich klare Aussagen und Empfehlungen der Behörden bezüglich COVID-19

Article about Ziemlich klare Aussagen und Empfehlungen der Behörden bezüglich COVID-19

Klarstellung der Corona Regeln

1. Im Prinzip dürfen Sie das Haus nicht verlassen, aber wenn Sie es möchten, dann dürfen Sie es schon.

2. Masken sind nutzlos, aber Sie sollten unbedingt eine tragen, denn sie kann Leben retten.

3. Alle Läden sind geschlossen, außer die, die geöffnet sind.

4. Dieses Virus ist tödlich, aber dennoch nicht allzu beängstigend, außer dass es eventuell zu einer globalen Katastrophe führt

5. Jeder muss ZUHAUSE bleiben, aber es ist wichtig auch RAUSZUGEHEN, besonders bei Sonnenschein, aber es ist besser, nicht rauszugehen, außer natürlich für Sport, aber eigentlich NEIN ...

6. Es gibt keinen Mangel an Lebensmitteln im Supermarkt, aber es gibt viele Dinge, die fehlen und andere sind zur Zeit nicht da.

7. Das Virus hat keine Auswirkungen auf Kinder, außer auf diejenigen, auf die es sich auswirkt..

8. Tiere sind nicht betroffen, aber es gibt immer noch eine Katze, die im Februar in Belgien positiv getestet wurde, als sonst noch niemand getestet wurde, plus ein paar Tiger hier und da und selten Hunde, eigentlich keine Hunde, aber manchmal doch auch schon ...
Jegliche Oberflächen, ausser das Fell ihres Haustieres, können die Krankheit natürlich übertragen.

9. Sie werden viele Symptome haben, wenn Sie krank sind, aber Sie können auch ohne Symptome krank werden, Symptome haben, ohne krank zu sein, oder ansteckend sein, ohne Symptome zu haben, sowie visa versa.

10. Das Virus bleibt auf verschiedenen Oberflächen zwei Stunden lang aktiv, nein vier, nein sechs, nein, habe ich Stunden gesagt, vielleicht Tage? Aber es braucht eine feuchte Umgebung. Aber eigentlich nicht unbedingt.
Das Virus bleibt eigentlich nicht in der Luft, aber öfter mal schon. Vor allem in einem geschlossenen Raum..
Es handelt sich hier grundsätzlich nicht um Schmierviren aber eine Schmierinfektion wäre möglich.

11. Wir sollten so lange eingesperrt bleiben, bis das Virus verschwindet, aber es wird nur verschwinden, wenn wir eine kollektive Immunität erreichen, also wenn es zirkuliert..
Dafür dürfen wir nicht zuviel eingesperrt sein, deswegen bleiben sie besser die meiste Zeit über Zuhause.

12. Sollten Sie erkrankt gewesen sein, werden Sie möglicherweise später wieder erkranken, dazwischen sind Sie imun.

;-)

Quelle: Behördenaussagen/WhatsApp


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR

Martin Signer

1 month ago

Omnia Wellness Enters into a Share Exchange and Reorganization Agreement with Bed Therapies

Omnia Wellness, Inc. (OTC: OMWS) announced that it has entered into a Share Exchange and Reorganization Agreement with a Denver-based privately held company Bed Therapies, Inc. pursuant to the Exchange Agreement, Omnia Wellness will acquire 100% of the issued and outstanding shares of the capital stock of Bed Therapies, and the shareholders of Bed Therapies will exchange such shares for newly issued shares of Omnia Wellness.  As a result, the former shareholders of Bed Therapies would own approximately 90% of the post-transaction outstanding shares of Omnia Wellness. The closing of the transaction is expected to occur in the second quarter of 2020 and is subject to closing conditions set forth in the Exchange Agreement.

Omnia Wellness and Bed Therapies are seeking to consummate this transaction to position the combined company to better commercialize its proprietary brand and market disruptive massage technology “Solajet” (www.solajet.com), as a unique and innovative Dry-Hydrotherapy technology, which provides deep tissue suppression, therapeutic heat, and a flushing full-body “wave” stimulation, by combining 3 therapies in 1. Therapeutic treatments are designed to deliver similar patient benefits as it compares to an hour-long deep tissue massage in as little as 15 minutes at an affordable price.

In the near future, Omnia Wellness and Bed Therapies will be creating a national chain of “MassageWave® Relaxation and Therapeutic Centers”, with the first  MassageWave® centers expected to open in Q4 of 2020, and “BodyStop® Recovery Zones” which are expected to be made available at fitness clubs across the country.


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR

Martin Signer

1 month ago

New roles in Marketing and Communications team in Skanska

Skanska commercial development business unit in CEE has created new roles within the Marketing and Communications team. Anna Wiśniewska has been appointed Marketing & Communications Director, while Alexandra Bucur and Petra Machartová have been promoted to Project Marketing & Communications Manager and Corporate Marketing Manager, respectively.

 

Skanska commercial development business unit in CEE is an office real estate market leader that operates on 10 city markets in 4 countries: Czech Republic, Hungary, Romania, and Poland. In January 2020 the company appointed a new Senior Leadership Team and initiated the process of centralizing the organization on a regional level in order to enhance cross-country cooperation, establish a regional business value creation hub, and strengthen the strategic focus on customers. New roles and appointments in the marketing and communications team are part of this process.

Anna Wiśniewska, previously Marketing & Communications Manager in Skanska’s commercial development business unit in CEE, has been promoted to Marketing & Communications Director position. In the new role, she manages a team of Marketing and Communications professionals across the business unit, i.e. in the Czech Republic, Hungary, Romania, and Poland. Anna Wiśniewska joined the company in 2011 and soon became the leader of the Marketing & Communications team, first in Poland and later on the regional level. Apart from coordinating all the marketing and communications activities, she introduced new brand products to the company and the market – Workplaces by Skanska and Futureproof Workplaces by Skanska as well as developed the Futureproof marketing strategy and created a unique product standard – Scandinavian Lobby Guidelines for the CEE region.

Alexandra Bucur, newly appointed Project Marketing & Communications Manager, is responsible for creating one project marketing and communications team for the entire business unit across the 4 countries. Project marketing and communication team will work on bringing office buildings to the market, by co-creating them, their positioning and messaging. Together with Project Management and Leasing & Sales teams, will also oversee delivering brand loyalty on each market. She has more than 12 years of experience as a professional and innovative marketer, building brands from scratch, developing products and leading diverse teams. Alexandra joined Skanska in 2016 as a Marketing and Communications Manager responsible for the Romanian and Hungarian markets. She developed and managed the marketing and communication plans for projects in these countries, while simultaneously coordinating Skanska corporate marketing and communications activities.

Petra Machartová, as a new Corporate Marketing Manager, works on the business unit level, cooperates closely with corporate communications as well as with project marketing and communications teams in order to increase projects’ awareness, create interest in the products, build and maintain brand loyalty. The main responsibilities in this role will be to create new and utilize existing marketing tools and support the key client and customer care programs as well as divestment events and materials. Petra will be responsible for the promotion of the Skanska commercial development unit portfolio to key clients and main target groups. She joined Skanska Property Czech Republic in 2012 and three years later was appointed Marketing & Communication Coordinator. Since then she managed to successfully execute the marketing and brand strategy for 5 commercial projects in Prague and support Skanska commercial development unit in the Nordics in building innovation strategy and supporting innovation culture in her assignment in Stockholm.

 

Aleksandra Markiewicz continues to be responsible for communications on CEE level and performs a new position of the Corporate Communications Manager. In this role, she is responsible for setting a centralized internal and external communications strategy for the entire commercial development business unit in CEE together with her team. She joined Skanska in 2012 as the Marketing & Communications Coordinator dedicated to projects in Wrocław, Katowice, and Kraków. Later she was given different roles within Skanska Group including an assignment in the communications team in Stockholm and managing the external communication team for three business streams in Poland (construction, residential and commercial development).


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR

Martin Signer

1 month ago

ViralClear Pharmaceuticals, Inc. (“ViralClear”), a subsidiary of BioSig Technologies submitted an application for Vicromax through the Coronavirus Treatment Acceleration Program

On April 16, 2020, ViralClear Pharmaceuticals, Inc. (“ViralClear”), a subsidiary of BioSig Technologies, Inc. (the “Company”), submitted an application for Vicromax (Merimepodib or MMPD) through the Coronavirus Treatment Acceleration Program (CTAP) to administer the drug to hospitalized patients with COVID-19.

Anti-viral candidate merimepodib targets RNA-dependent polymerases. The molecule has shown activity against a broad spectrum of RNA viruses and has demonstrated satisfactory safety data from over 300 patients treated for hepatitis C. Recently, ViralClear published its first pre-clinical data generated under contract with Galveston National Laboratory at The University of Texas Medical Branch. A manuscript titled “The IMPDH inhibitor merimepodib suppresses SARS-COV-2 replications” was authored by Natalya Bukeryeva, Emily K. Mantlo, Rachel A. Sattler, Cheng Huang, Slododan Paessler, DVM, Ph.D of the UTMB Galveston National Laboratory and Jerome Zeldis, M.D., Ph.D of ViralClear. In-vitro studies referenced in the manuscript demonstrated that merimepodib decreased viral production by over 98%.     


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR

Martin Signer

1 month ago

How Masks and Protective Gear Help Taking Up Business Again

While masks have been on shortage supply, in the mean-time procurement difficulties should not be a valid excuse anymore. 

Should you face difficulties in the procurement process, please contact Mostafa Shalaby from Swiss Terahertz LLC

There are some good articles how e.g. Taiwan responded to it

Unfortunately, in Europe and North America the learning process is also in this regard very slow (also the first step was hugely delayed).


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR

Martin Signer

1 month ago

Simulations Help Understanding the Future of the COVID-19 Pandemic

As I did my diploma thesis in quantitative finance also in a simulation study with a scenario generation model with moment matching transformations, I truly appreciate the insights from simulation work in giving the visualization and seeing the dependencies and it might also give an outlook to when it ends.

For the COVID-19 outbreak, I have seen a few excellent - also interactive - simulations and data-based forecasting, I would like to share here, as the insights are very helpful for informed decisions with the appropriatecurrent data.

You can also check the latest data on the COVID-19 outbreak with interactive charts

or this article.


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR

Martin Signer

1 month ago

Deutscher Gewerbebereich in hohem Ausmaß von Mietausfällen betroffen

„Unsere neue Mitgliederumfrage zeigt: Der Gewerbe-bereich ist derzeit in hohem Ausmaß von Mietausfällen betroffen. 70 Prozent der Mietausfälle stammen aus Verträgen mit dem Einzelhandel, Gastronomie und dem Hotelbereich. Hier ist in besonderem Maße staatliche Hilfe für Gewerbemieter und Vermieter erforderlich, etwa durch Ausfallbürgschaften für gestundete Mieten“, so Andreas Ibel, Präsident des BFW Bundesverbandes Freier Immobilien- und Wohnungsunternehmen, heute in Berlin. Ibel präsentierte die neue Umfrage unter den mittelständischen BFW-Mitgliedsunternehmen. Die Auswertung der bundesweiten Umfrage umfasst 230.000 Mietverhältnisse in Wohn-Segment und 16.000 Mietverhältnisse im Gewerbebereich.

Demnach haben bundesweit 19 Prozent der befragten Immobilienunternehmen Mietausfälle im Gewerbebereich. In Bayern berichten 28 Prozent der befragten Unternehmen von ausbleibenden Zahlungen von Gewerbemieten, in Berlin 20 Prozent und in Nordrhein-Westfalen 15 Prozent.

Entscheidend ist dabei aber der Blick auf die individuellen Unternehmen: Abhängig von der Zusammensetzung der Bestände und der jeweiligen Branche bietet sich hier ein sehr heterogenes Bild. „Während manche Unternehmen gar nicht oder nur in geringem Maße von Mietausfällen betroffen sind, verzeichnen andere Zahlungsausfälle bei bis zu 80 Prozent der Gewerbemietverhältnisse. Dann steht die Existenz des Unternehmens durch die ausbleibende Liquidität auf dem Spiel“, warnte Ibel.

„Was wir jetzt brauchen, ist ein Bündel an unterschiedlichen, passgenauen Maßnahmen, die gemeinsame Perspektiven für Mieter und Vermieter aufzeigen“, so Ibel weiter. „Das gilt ganz besonders für den Einzelhandel, die Gastronomie und die Hotellerie, in vom shut-down in den vergangenen Wochen am stärksten betroffen waren. Hier sind nicht nur Sofort-Hilfen, sondern längerfristige Maßnahmen für einen nachhaltigen Wiederaufbau gefragt. Ausfallbürgschaften für gestundete Mieten können dabei Sicherheit für Mieter und Vermieter schaffen.“

„Es ist der Einzelhandel, die Gastronomie und der Tourismus, die das Erscheinungsbild und das Lebensgefühl vieler Städte und Kommunen prägen“, resümiert der BFW-Präsident. „Auch wenn die jetzt beschlossenen Lockerungen bei den Öffnungen Hoffnung machen, müssen Mieter und Vermieter im Gewerbebereich noch stärker unterstützt werden. Sonst drohen neben den wirtschaftlichen Auswirkungen auch negative Entwicklungen für unsere Innenstädte und unser gesellschaftliches und kulturelles Leben!“


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR

Martin Signer

1 month ago

Onda Group Meets Demand for Cheaper Energy during the COVID-19 Crisis

Onda Group a Pre-eminent Player in the Southern Italy Energy Market Meets Demand for Cheaper Energy during the COVID-19 Crisis

17 April 2020, Syracuse, Sicily – Onda Group, a preeminent supplier of energy to Southern Italian businesses, homes, and local utilities, announces that it is ready to supply cheaper energy for restarting the economic engine of the region by supplying lower-cost energy alternatives for its customers. With the sharp drop in oil & gas prices and the huge disruption of the Italian economy, Onda plans to supply the region with cheaper energy alternatives that have not been seen in prices for the last 30 years. 
 
 
Cheaper energy means that the regions of Sicily, Sardegna, and the Southern Italian mainland should see a resurgence of economic activity partly due to lower energy costs provided by Onda. Onda will bring to the market a technological “Killer Application” able to collect new clients and keep them forever. A smart meter provides the consumption in €, of a single device (lamps, fridges, ovens, etc). Its name is Efficento, and it is a unique technology in the European market.

As Italy recovers from the COVID-19 pandemic, Onda is poised to help jump-start this economy by providing low-cost energy products to its customer base, and the company plans to rapidly expand and increase its market share in this region. The company CEO, Luigi Martines, states “Onda will make all efforts to sell its customers energy at low prices in order to get the Italian economy moving again. It is our responsibility as energy suppliers, to pass savings on to our customers for a quick and sustainable recovery. We expect to increase overall sales and expand our services in Sicily, Sardegna, and Southern Italy to make Onda a decisive player in the energy markets in the near future.”
 
Learn more about Efficento here
 

About Onda Group.

The Wave Group has operated in the energy trading and gas industry in Italy for about 20 years. The historical sites are on two islands, Sicily and Sardinia, and the registered office is in Rome.

Onda Group was created shortly after the market liberalization of electricity in Italy in 2003. Today, they have about 35,000 customers, mainly in the islands, and a turnover of €30 million.

Thanks to years of research (funded by European Community funds), and a partnership with Voltaware, a manufacturer of technologies, Onda Group now features a "Killer Application" in Italy and soon in Europe, able to increase sales but, more importantly, contribute to customer loyalty, the main KPI industry.

Customers of Wave, thanks to "Efficiento", will be able to know in real-time and in their bills as they consume € in individual loads in their home (fridge, oven, lights, TV, etc).


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR

Martin Signer

2 months ago

Die Crypto Finance AG hat erfolgreich ihre Series B-Finanzierungsrunde über CHF 14 Millionen abgeschlossen

Die Crypto Finance AG hat erfolgreich ihre Series B-Finanzierungsrunde über CHF 14 Millionen abgeschlossen. Die Finanzierung wurde vom Schweizer Investor Rainer-Marc Frey und der in Asien ansässigen Lingfeng Capital angeführt. Zusätzlich beteiligten sich mehrere bestehende sowie neue Investoren. Weiter wird Dr. Ming Shu, Partner bei Lingfeng Capital, als neues Vorstandsmitglied der Crypto Finance AG vorgeschlagen. Mit dem Abschluss dieser Runde wird die Crypto Finance Gruppe die internationale Expansion weiter vorantreiben und ihre Aktivitäten im Bereich Asset Management, Trading, Tokenisierung und Storage-Lösungen für institutionelle Anleger weiterentwickeln.

16. April 2020, Zug, Schweiz. Die Crypto Finance AG hat ihre Series B-Finanzierungsrunde über CHF 14 Millionen erfolgreich abgeschlossen. Mit diesem zusätzlichen Kapital steigt das bisher aufgenommene Kapital auf insgesamt CHF 36 Millionen. Die Gruppe kann ihre Expansion, trotz den anhaltenden Herausforderungen durch Covid-19, somit weiter ausbauen. Dies ist eine enorme Leistung und zeugt vom Erfolg des bisher erreichten und der Unternehmensstrategie. Jan Brzezek, CEO und Gründer der Crypto Finance AG, äussert sich: «Ich freue mich sehr, die Neuigkeiten über unsere Finanzierungsrunde zu verkünden. Wir können somit unsere Vision und Strategie wie geplant weiterverfolgen und auch in Zukunft marktführendes und professionelles Asset Management, Trading und Infrastrukturlösungen für digitale Anlagen anbieten.»

Die Finanzierungsrunde wurde vom renommierten Schweizer Investor Rainer-Marc Frey und dem in Asien ansässigen Private Equity Fund Lingfeng Capital angeführt. Zusätzlich teilgenommen haben mehrere bereits bestehende sowie neue Investoren aus Europa und Asien, wie auch die asiatische QBN Capital. Für die erfolgreiche Vermittlung von Investoren mit dem richtigen strategischen Fokus und Fachwissen hat das Asien-Team der Crypto Finance AG mit PricewaterhouseCoopers Limited in Hong Kong zusammengearbeitet.

«Die fortschrittliche Regulierung und das pulsierende Crypto-Ökosystem überzeugten QBN in der Schweiz zu investieren. Die Crypto Finance AG gehört zu den Besten im Crypto-Sektor und der Handel von digitalen Anlagen wird immer wichtiger. Wir können also viel vom Erfahrungsschatz in der Schweiz für die Zukunft lernen», erklärt Dr. Frank Tong von QBN Capital.

Dr. Ming Shu von Lingfeng Capital stimmt dem zu: «Das Team bei Lingfeng ist vom Management und der Strategie der Crypto Finance AG sehr beeindruckt. Wir beteiligen uns an aufstrebenden Crypto-Unternehmen, die innerhalb regulierten Rahmenbedingungen agieren und gleichzeitig eine umfangreiche Erfahrung in der traditionellen Finanzbranche haben. Wir freuen uns darauf, mit der Crypto Finance Gruppe eine Brücke zwischen Europa und Asien zu schlagen und die Annäherung von traditionellen und digitalen Anlagen zu ermöglichen.»

Bereits über 50% der Geschäftstätigkeit der Gruppe kommt von internationalen Kunden. Die neuen finanziellen Mittel werden für die weiterführende internationale Expansion, wie auch für die Weiterentwicklung von Produkten und Dienstleistungen eingesetzt. Dadurch werden weitere Kunden vom sicheren und zuverlässigen Angebot, welches die Crypto Finance Gruppe bereits heute einer wachsenden Anzahl internationalen und institutionellen Investoren zur Verfügung stellt, profitieren können.

Jan Brzezek und der Vorstand der Crypto Finance AG freuen sich, mitteilen zu können, dass Dr. Ming Shu, Partner bei Lingfeng Capital, an der Generalversammlung als neues Vorstandsmitglied der Crypto Finance Gruppe vorgeschlagen wird. Dr. Shu hat ein weitreichendes regulatorisches und Finanz-Netzwerk sowie umfangreiche operative Erfahrung mit multinationalen Finanzinstitutionen, wie Henderson Global Investors oder Alibaba.
 
Über Lingfeng Capital
Lingfeng Capital ist ein Private-Equity-Fonds im Bereich Wachstumskapital für die FinTech-Branche im asiatisch-pazifischen Raum, insbesondere im Grossraum China. Fokussiert ist Lingfeng Capital auf reale Anwendungen und zugehörigen Technologien für die Finanzindustrie. Ihre Vision ist der führende Fonds im Bereich Innovationstechnologie im Finanzbereich zu werden und der neusten Generation von unternehmerisch-denkenden Fintechs Wachstum und Erfolg zu ermöglichen. Lingfeng Capital
 
Über QBN Capital
QBN Capital ist ein technologie-fokussierter Fonds, der sich auf Fintech- und Deep-Tech-Unternehmen spezialisiert hat, welche das Ziel und Potential haben, ihre Geschäftstätigkeit nach China zu skalieren. Sie bieten Portfolio-Unternehmen mit ihren Investoren- und Businessnetzwerken in dieser Region tatkräftige Unterstützung. QBN Capital
 
Über die Crypto Finance Gruppe
Die Crypto Finance Gruppe bietet institutionellen und professionellen Investoren Produkte und Dienstleistungen, welche im Crypto-Bereich weltweit führend sind. Zur Gruppe gehören die Holdinggesellschaft Crypto Finance AG, mit Sitz im Crypto Valley in der Schweiz, und die drei operativen Tochtergesellschaften: Die Crypto Fund AG, der erste von der FINMA zugelassene Vermögensverwalter für Crypto-Assets; die Crypto Broker AG, welche im 24/7 Handel mit Crypto-Assets tätig ist; und die Crypto Storage AG, welche Infrastruktur- und Tokenisierungslösungen für Crypto-Assets bereitstellt. Das mehrfach ausgezeichnete Schweizer Fintech-Unternehmen hat erfolgreich die Brücke zwischen der traditionellen Finanzwelt und den digitalen Anlagen gebaut. Crypto Finance Group

Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR

Martin Signer

2 months ago

TradeStation Crypto Connects to ErisX to Further Increase Trading Liquidity

TradeStation Crypto expands its connectivity with the addition of ErisX quotes and liquidity to its platform

 

PLANTATION, Fla. - TradeStation Crypto, Inc. (“TradeStation Crypto”), a subsidiary of TradeStation Group, Inc. (“TradeStation Group”), announced yesterday that customers have access to quotes and liquidity from ErisX’s spot market for digital assets including Bitcoin (BTC), Bitcoin Cash (BCH), Ether (ETH) and Litecoin (LTC). This combined effort furthers TradeStation Crypto’s goal to expand its connectivity in order to provide traders with better price visibility, deeper liquidity, and streamlined access to the crypto markets.

 

“We are thrilled to add ErisX’s quotes and liquidity to our service. Adding this digital-asset exchange relationship helps improve our customers’ view of prices across more connected markets,” said James Putra, Director of Product Strategy, TradeStation Crypto. “At TradeStation Crypto, our goal is to deliver one of the deepest liquidity pools in the crypto market, and this new collaboration with ErisX is a key element of our strategy as we look to achieve that goal.”

 

TradeStation Crypto unlocks access to cryptocurrency trading through the trusted and familiar TradeStation brand, an established name in the online trading technology and brokerage industry for active and serious traders. The TradeStation brand brings a mature market mindset to the crypto markets and seeks to provide self-directed traders with deeper market liquidity and innovative pricing. Through TradeStation Crypto’s new relationship with ErisX, the two companies are working together to mature the market structure and help enable mainstream access to the crypto markets.   

 

“TradeStation Crypto and ErisX share a mission to simplify access to the crypto markets and a belief that digital assets should be accessible to those investors who want to add them to their broader portfolio,” said Thomas Chippas, CEO, ErisX. “Working with an established brand like TradeStation brings our platform to a new wave of traders who crave a seamless and dependable trading experience for digital assets as they do with capital markets.”

 

To get started trading crypto, apply for an account through TradeStation Crypto’s seamless account opening process. Click here for more information.

About TradeStation Crypto, Inc.

TradeStation Crypto is a subsidiary of TradeStation Group, Inc. that offers cryptocurrency brokerage services for self-directed online traders. For more information about the benefits and features of TradeStation Crypto, please visit www.tradestationcrypto.com.

About TradeStation Group, Inc.

For more than 30 years, the TradeStation Group companies have been pioneering leaders in the online trading industry, committed to delivering the best trading technology, brokerage services, trading education, and support to individual and institutional traders. TradeStation’s award-winning trading and analysis platforms offer access to equities, options and futures trading at the major U.S. equities and options exchanges and market centers, as well as the major futures exchanges. TradeStation’s clients have access to the powerful tools needed to design, test, optimize, monitor and automate custom trading strategies, and its mobile and web trading apps allow clients to take the power of the TradeStation trading experience on the go.  TradeStation also provides a vast array of educational offerings to help beginning and advanced clients learn online trading and investing skills to help them meet their trading and investment objectives.

TradeStation Group has a minority non-controlling ownership interest in ErisX.

About ErisX

ErisX offers individuals and institutions a single, innovative platform to access digital asset spot and futures markets. By combining professional tools, advanced technology, sophisticated regulatory oversight, and a diverse product set, ErisX offers compliant, capital markets friendly workflows to digital market participants. Backed by some of the world’s largest trading firms and financial institutions, ErisX brings transparency and reliability to the digital asset class. ErisX, Eris Exchange, and the ErisX and Eris Exchange logos are trademarks of the Eris Exchange group of companies.

ErisX Futures are offered through Eris Exchange, LLC, a Commodity Futures Trading Commission (CFTC) registered Designated Contract Market (DCM) and Eris Clearing, LLC, a registered Derivatives Clearing Organization (DCO).  The CFTC does not have regulatory oversight authority over virtual currency products including spot market trading of virtual currencies.  ErisX Spot Market is not licensed, approved or registered with the CFTC and transactions on the ErisX Spot Market are not subject to CFTC rules, regulations or regulatory oversight. ErisX Spot Market may be subject to certain state licensing requirements.


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR

Martin Signer

2 months ago

Pilates


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR

Martin Signer

2 months ago

Todos Medical Expands on COVID-19Distribution Agreement with Shanghai Liangrun Subsidiary Gibraltar

Todos Medical Ltd. (TOMDF), a pre-commercial stage in vitrodiagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, announces that its President and Chief Executive Officer Gerald E. Commissiong has provided the following corporate update on the Company’s ongoing initiatives, including progress with its novel coronavirus (COVID-19) joint venture Corona Diagnostics, LLC,  the ongoing breast cancer commercialization trial with its proprietary blood spectroscopy platform, and the pending acquisition of its Alzheimer’s disease joint venture Breakthrough Diagnostics, Inc." type="text" style="margin: 10px 0;padding: 0;mso-line-height-rule: exactly;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%;color: #202020;font-family: Helvetica;font-size: 16px;line-height: 150%;text-align: left;">Todos Medical Ltd. (TOMDF), a pre-commercial stage in vitrodiagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, announces that its President and Chief Executive Officer Gerald E. Commissiong has provided the following corporate update on the Company’s ongoing initiatives, including progress with its novel coronavirus (COVID-19) joint venture Corona Diagnostics, LLC,  the ongoing breast cancer commercialization trial with its proprietary blood spectroscopy platform, and the pending acquisition of its Alzheimer’s disease joint venture Breakthrough Diagnostics, Inc.

Our distribution partner Gibraltar Brothers have entered into agreements to diversify its manufacturing supplies of Ab POC Test Kits for U.S. and select international sales to also include two additional POC Test Kits whose manufacturers have both already notified the U.S. Food and Drug Administration (FDA) of an Emergency Use Authorization (EUA) application, as well have both already received full Chinese National Medical Products Administration (NMPA) approval. Through our entities and teams in the U.S., Israel, and Singapore, we are working through the various regulatory and international import/export requirements in order to initiate sales in the United States and abroad. Given the tremendous competitive international demand for these Ab POC Test Kits, we felt it was important to accelerate corporate EUA-related application timelines so that we can begin discussions in earnest with prospective clients, as well as diversify our POC antibody test kit supply chain to ensure the timely delivery once orders are placed. We will seek to continue to expand this supply chain as we prepare for commercial launch, and continue to stay on the leading edge of the technology in the Ab POC Test Kit market given the rapidly evolving regulatory and international trade landscape in this field.

We are working with a leading pulmonologist in Southern California to clinically validate the initial fingerprick Ab POC Test Kit to which we gained rights last month. We expect to complete that validation process in the near future, after which we will notify the FDA of our prospective EUA application on behalf of Shanghai Liangrun’s original manufacturer later this month within the 15-day post-commercial launch window allowed by the FDA under EUA serology test guidelines. We have developed a strong working relationship with Shanghai Liangrun’s team and believe there may be areas for further collaboration in the future. We believe emerging concerns about the clinical utility of these Ab POC Test Kits will be overcome with proper US-based clinical validation to determine the most sensitive among them, innovation in the space with regards to the scientific literature evaluating other antibodies of interest in the future, as well as proper education regarding best practices for use by healthcare providers (HCPs), and therefore are also focused on engaging with HCPs to educate them on the appropriate role Ab Test Kits can play in the quickly evolving COVID-19 testing paradigm.  We also believe there will be a significant opportunity to use these Ab POC Tests for potential at-home testing strategies in combination with HCPs’ monitoring test administration and recording of results once the various appropriate safeguards are put in place to overcome the regulatory impediments that currently exist in the US. 

One of the biggest advantages of Ab POC Test Kits is that we will be able to identify those who have been previously exposed to COVID-19, as well as begin to understand whether this prior exposure confers immunity, or if long-term side effects emerge. This will be critically important as populations seek to begin to de-escalate isolation strategies so that we can understand who is most at-risk for initial infection, as well as monitor individuals for potential reinfection. While IgM is generally believed to upregulate in the blood roughly 2-7 days after initial infection and downregulate within 3-4 weeks after initial infection, IgG appears to upregulate roughly 10 days post-infection and may remain upregulated for significantly longer. It is believed IgG could remain upregulated for as long as three years post-infection, as has been seen in response to other viral infections. These biomarkers could be used to help establish individuals’ “COVID status,” thus presenting tremendous potential as a key tool as we seek to return to normal life. We believe, as do several experts in the field, that these biomarkers should be explored on a population basis in order to understand the true spread of the virus, and therefore we believe there will be a long-lasting opportunity for Todos to make a meaningful long-term impact for the benefit of our communities.

Despite certain unavoidable export delays in getting the shipment of 3DMed’s proprietary ANDiS®350 3DMed Automated Solution countertop real-time PCR (polymerase chain reaction) machine (3D Machine) and related RT-PCR test kits out of China, we are now preparing to receive those machines and complete the validation of the automation component of our PCR test kit strategy in our partner Provista’s lab in Alpharetta, GA as part of the research validation studies required for CLIA certification. We have reviewed the specifications of dozens of other PCR test kit manufacturers, and believe 3DMed’s systems may be one of the best systems on the market due to its ability to consistently detect very low viral copy count. While some POC PCR systems provide physicians with ease of use, we have identified the increased potential among those other systems for false negatives as high viral copy count specifications may result in missed early (or late) diagnosis due to the virus being present in low concentration in the oropharyngeal or nasopharyngeal structures at the time of sample collection. As such, we are taking the approach that a simple antibody blood screening tool may be helpful, in combination with other risk factors, in stratifying the patient population ahead of advancing patients to more sensitive diagnostic PCR testing with 3DMed’s systems and reagents.

Additionally, given that 3DMed is able to test for COVID-19, as well as influenza A and influenza B, there is a potentially reduced risk of retesting and/or readmission of a patient with a negative COVID-19 test result because many of those negative patients, who have historically suffered from the flu which presents with clinical symptoms similar to COVID-19, would not receive a definitive diagnosis without this additional influenza A or influenza B nucleic acid test. As a result, they would likely need to come back to the physician for additional testing, thereby putting further strain on already-stretched healthcare systems at the current time, while also putting themselves and others at increased risk of infection. 

We also have begun non-automated PCR validation in the lab because we are now evaluating offering COVID-19 stool testing service given the emerging body of evidence that suggests the virus may reside in the gastrointestinal (GI) tract while the viral load in the upper respiratory tract is in decline. Additionally, there is significant heterogeneity in the individual operator oropharyngeal or nasopharyngeal samples collection process in addition to patient heterogeneity of oropharyngeal or nasopharyngeal viral load at different time points in the course of the disease. These challenges lead to potential false negatives and create more opportunities for the virus to spread. This GI tract approach requires further validation to fully understand its impact on disease diagnosis, monitoring, and prognosis.

The objective with this dual Ab POC Test kit/PCR strategy is to establish a highly scalable protocol using the antibody test kits to help physicians quickly triage patients into risk categories (high risk, medium risk, low risk, no risk) using the IgM/IgG test, in combination with clinical symptoms and other measures, and advance only those at higher risk based on policymakers’ decision-making to guide access to PCR testing.  This would allow policymakers to focus on limited PCR testing resources on patients at higher risk of poor outcomes to the more expensive and invasive PCR testing. We believe with this strategy that we can increase patient throughput for HCPs and begin to reduce the backlog on the PCR testing system, while simultaneously improving PCR testing throughput with 3DMed’s automated extraction platform, in addition to the other platforms that are coming online. We believe that many governments, HCPs, and payors (self-insured employers and insurance companies) will be looking for comprehensive testing solutions that will allow them to reintegrate people back into the workforce, and as such being a “one-stop-shop” for all testing needs could be a valuable niche in the long run. In the short term, this strategy will allow us to broadly distribute the POC antibody test kits to HCPs while reflexing positive results to PCR testing and work to develop compliant telemedicine solutions that allow for the use the POC test kits at home where potentially two consecutive negative tests several days apart could provide the initial certification to get back to work. We intend to provide further clinical and commercial updates as key milestones in this program are achieved.

The Company has continued to advance its ongoing European pre-commercial breast cancer clinical trial in Romania investigating our proprietary TBIA spectroscopy platform using Fourier Transformed Infrared Analysis (FTIR) with our European commercial partner Orot+ (a division of Luces-Orot). The ongoing clinical trial for our breast cancer screening tests for dense breasts (TMB-2) and for all breast densities (TMB-1) has recruited nearly 50% of the subjects needed to satisfy the requirements for commercial launch in Europe under our CE mark, despite a significant recent slowdown due to COVID-19. We expect to complete enrollment for this study later in the year, with an expected launch immediately thereafter. 

Concurrent with today’s update, the Company is announcing that it has received a notice of allowance from the U.S. Patent & Trademark Office covering the use of our TBIA FTIR platform to identify benign ovarian tumors. This pending patent issuance complements our existing intellectual property portfolio that covers the use of our TBIA FTIR platform to detect malignant solid tumors. 

To complete the acquisition of Breakthrough Diagnostics due to the tremendous potential of the LymPro Test™ as a diagnostic blood test for Alzheimer’s disease. We have commissioned an independent third-party valuation of LymPro in order to fulfill the necessary requirements to complete the acquisition later this quarter. We believe that a blood test for Alzheimer’s disease remains one of the most elusive and valuable diagnostic tests sought by medical professionals. We further believe that our solution may fundamentally impact how we address Alzheimer’s disease by allowing for early diagnosis and early enrollment into clinical trials.  It may also assist in the development of new therapeutic strategies that have greater success in treating Alzheimer’s disease at its earliest stages, prior to significant brain damage.

We remain on track to complete the proposed listing of Todos’ shares onto the Nasdaq CM™ marketplace, as well as complete the acquisition of Provista Diagnostics in the second quarter of 2020 to gain ownership of its proprietary commercial-stage negative predictive value breast cancer blood test Videssa® and its CLIA/CAP certified lab. 

At the beginning of this year, we certainly did not expect to be entering the second quarter with a key focus on a novel viral disease that caused a global pandemic. Notwithstanding this, we saw the tremendous need to bring our diagnostic expertise to the forefront to combat this complex virus, and believe our expertise could help mitigate the overwhelming economic destruction COVID-19 has unleashed on world economies, in particular in the United States. We believe we are well-positioned to execute upon our diagnostic testing paradigm, which is ultimately quite similar to other testing paradigms we are developing for cancer and Alzheimer’s disease, and are proud to stand in solidarity with our colleagues in the fight against COVID-19. As we look to make an impact on this disease by bringing our expertise to bear, we are in awe at our colleagues in the scientific, medical and policymaking fields who have all rallied around this global fight against the virus. We believe that this is a fight we can contribute to and that together with our colleagues in the scientific, medical and policy fields we can win.

Lastly, they continue to work toward a NASDAQ listing for Todos’ common stock in the second quarter of 2020. I thank you for taking the time to read this update and look forward to sharing progress with you as we move forward.

Coronaviruses are a family of viruses that can lead to respiratory illness, including Middle East Respiratory Syndrome (MERS-CoV) and Severe Acute Respiratory Syndrome (SARS-CoV). Coronaviruses can be transmitted between animals and people and evolve into strains not previously identified in humans. On January 7, 2020, a novel coronavirus (SARS-CoV-2) was identified as the cause of pneumonia cases in Wuhan, Hubei Province of China, and additional cases have been found in a growing number of countries worldwide. COVID-19 is a disease caused by SARS-CoV-2.

TOMDF engineers life-saving diagnostic solutions for the early detection of a variety of cancers. The Company's state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that deploys deep examination into cancer's influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Todos' two internally-developed cancer-screening tests, TMB-1 and TMB-2, have received a CE mark in Europe and are currently in a pre-commercial study with its distribution partner Orot+ (a division of Luces-Orot). Todos recently entered into an exclusive option agreement to acquire U.S.-based medical diagnostics company Provista Diagnostics, Inc. to gain rights to its Alpharetta, Georgia-based CLIA/CAP certified lab and Provista's proprietary commercial-stage Videssa® breast cancer blood test. The transaction is expected to close in the second quarter of 2020. engineers life-saving diagnostic solutions for the early detection of a variety of cancers. The Company's state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that deploys deep examination into cancer's influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Todos' two internally-developed cancer-screening tests, TMB-1 and TMB-2, have received a CE mark in Europe and are currently in a pre-commercial study with its distribution partner Orot+ (a division of Luces-Orot). Todos recently entered into an exclusive option agreement to acquire U.S.-based medical diagnostics company Provista Diagnostics, Inc. to gain rights to its Alpharetta, Georgia-based CLIA/CAP certified lab and Provista's proprietary commercial-stage Videssa® breast cancer blood test. The transaction is expected to close in the second quarter of 2020.

AMBS), Todos is also actively involved with the development of blood tests for the early detection of neurodegenerative disorders, such as Alzheimer's disease. Todos expected to complete the remaining unowned interest in Breakthrough in the second quarter of 2020."

Todos recently entered into distribution agreements with China-based companies to distribute certain novel coronavirus (COVID-19) test kits. The Company has entered into distribution agreements covering the U.S. and Israel with Gibraltar Brothers & Associates, LLC, a U.S.-based subsidiary of Shanghai Liangrun Biomedicine Technology Co. (Shanghai), for its proprietary colloidal gold immunochromatography (Colloidal Gold) point-of-care IgM/IgM-based antibody test kits, and with 3DMedicine Science & Technology Co (3DMed), a China-based cancer precision medicine company, for distribution in the U.S. and Israel of its ANDiS® SARS-CoV-2 Detection Kit (COVID), ANDiS® SARS-CoV-2 & Influenza A/B Detection Kit (COVID/Flu) and its proprietary ANDiS®350 3DMed Automated Solution countertop real-time PCR machine (3D Machine). Todos has formed Corona Diagnostics, LLC, a joint venture with Emerald Organic Products, Inc.  (EMOR), to support the commercialization of its COVID-19 testing paradigm.

Certain statements contained in this press release may constitute forward-looking statements. For example, forward-looking statements are used when discussing our expected clinical development programs and clinical trials. These forward-looking statements are based only on current expectations of management and are subject to significant risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for product candidates; competition from other biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; and laboratory results that do not translate to equally good results in real settings, all of which could cause the actual results or performance to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Todos Medical does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Todos Medical, please refer to its reports filed from time to time with the U.S. Securities and Exchange Commission.

 
 

Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR

Martin Signer

2 months ago

Citius Pharmaceuticals signed contract for ARDS treatment with Novellus

Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, signed an exclusive six-month option agreement to in-license a stem-cell therapy for acute respiratory distress syndrome (ARDS) from a subsidiary of Novellus, Inc., a preclinical-stage biotechnology company based in Cambridge, MA.

Novellus's patented process uses its exclusive non-immunogenic synthetic messenger ribonucleic acid (mRNA) molecules to create induced pluripotent stem cells (iPSCs) that, in turn, generate mesenchymal stem cells (MSCs) with superior immunomodulatory properties. MSCs have been shown to be safe in over 900 clinical trials and to be safe and effective in treating a number of inflammatory diseases, including ARDS.

"ARDS is the most common cause of respiratory failure and mortality in COVID-19 patients. Currently, there is no proven treatment for ARDS. Literature supports the use of counter-inflammatory MSCs for ARDS, and papers published in China have shown that at least seven COVID-19 patients with ARDS responded to MSC therapy. Clearly this is an avenue that shows promise and should be pursued as a potential treatment for ARDS. We believe Novellus is at the forefront of creating allogeneic, iPSC-derived MSCs. These cells have the potential to overcome the limitations of MSCs derived from adult donors, which are telomere shortened and introduce variability into the manufacturing process," said Citius Chief Executive Officer Myron Holubiak.

Novellus Chief Science Officer Matt Angel, Ph.D., stated, "Using our mRNA-based cell-reprogramming technology, Novellus can provide a near-unlimited supply of MSCs for treating patients with ARDS, including those critically ill from COVID-19. These will be allogeneic ('off-the-shelf') cells that in vitro have demonstrated much greater expansion potential and much higher immunomodulatory protein expression than donor-derived MSCs. We are excited to employ our technology to such an urgent medical crisis and believe that our MSCs represent an ideal source of cells to be used in this extremely important development effort."

Holubiak added, "No effective pharmacotherapy for ARDS exists, and ARDS-related morbidity and mortality are high. MSCs have been studied in the treatment of lung injury, and we aim to build upon this work with Novellus's iPSC-derived MSCs to improve the immunomodulatory response in humans. We have assembled a team of experts who are dedicated to advancing this project to an Investigational New Drug (IND) application as quickly as possible."  

About ARDS
Acute respiratory distress syndrome (ARDS) is a type of respiratory failure characterized by the rapid onset of widespread inflammation in the lungs. ARDS is a rapidly progressive disease that occurs in critically ill patients – most notably now in those diagnosed with COVID-19. ARDS affects approximately 200,000 patients per year in the U.S., exclusive of the current COVID-19 pandemic, and has a 30% to 50% mortality rate. ARDS is sometimes initially diagnosed as pneumonia or pulmonary edema (fluid in the lungs from heart disease). Symptoms of ARDS include shortness of breath, rapid breathing and heart rate, chest pain, particularly while inhaling, and bluish skin coloration. Among those who survive ARDS, a decreased quality of life is relatively common.

About Citius Pharmaceuticals, Inc.
Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care. For more information, please visit www.citiuspharma.com.

About Novellus, Inc.
Novellus is a pre-clinical stage biotechnology company developing engineered cellular medicines using its non-immunogenic mRNA, nucleic-acid delivery, gene editing, and cell reprogramming technologies. Novellus is privately held and is headquartered in Cambridge, MA. For more information, please visit www.novellus-inc.com.

 

Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR

Martin Signer

2 months ago

Fluxus CEO Fanyu Lin to serve on World Economic Forum’s Global Internet of Things Council

 

 

Fluxus CEO Fanyu Lin will serve on the World Economic Forum’s Global Internet of Things (IoT) Council, to help steward the Forum’s effort in shaping the global agenda on IoT at a time of rising public interest in the technology’s social and economic implications.

“The rapid spread of coronavirus has shaken our businesses, our governments, and our societies. It has also underscored the critical role that technology and technology governance can – and must – play in strengthening our global resilience and readiness in times of crisis. 

Now, more than ever, we need global leaders from government, industry, the start-up community, civil society, and academia to come together to provide strategic guidance to the international community on governance and cooperation priorities for emerging technologies. There is currently no place in the international system where this kind of high-level, strategic dialogue on the governance of IoT across stakeholders and regions takes place on an ongoing basis.”

– Jeff S. Merritt, Head of Internet of Things, Robotics and Smart Cities, World Economic Forum

It is estimated by Cisco that IoT can inject $14 trillion of economic value to the global economy by 2030. According to the Council’s research, issues related to how the benefits of IoT will be distributed fairly in society are identified as the largest governance gap. The Council is driving collective actions towards reaching a global baseline consensus on governance across the IoT ecosystem to maximize the positive benefits and minimize harm economically, socially and environmentally, for all of society.

“From intelligent manufacturing to grid optimization to our connected homes, the incremental adoption of IoT in housing-related industries is not only paving ways for a smarter construction model to occur, but also pushing the boundaries of what a smart home can mean for communities from the bottom of the pyramid across the economic spectrum.” – Fanyu Lin, CEO of Fluxus.

 

 

 

Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR

Martin Signer

2 months ago

Possible treatments for COVID-19

Article about Possible treatments for COVID-19

Will one of these drugs give remedy?


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR

Martin Signer

2 months ago

When will a vaccine for COVID-19 be here?

Article about When will a vaccine for COVID-19 be here?

As 

 

and the interactive charts show COVID-19 will stay annoying for quite some time and will cause huge required efforts.

So let's hope for relief by a vaccine.


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR

Martin Signer

2 months ago

Interactive charts with current data for COVID-19

You can choose the countries in the charts, and also change the scale logarithmic/linear

        •  

 

Thanks to the authors/source

Max Roser, Hannah Ritchie and Esteban Ortiz-Ospina (2020) - "Coronavirus Disease (COVID-19) – Statistics and Research"

 


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR

Martin Signer

2 months ago

Interaktive Charts zur COVID-19-Pandemie mit aktuellen Zahlen

In den Graphen kann man Länder wählen, die Skala (logarithmisch/linear) wählen, die Datenquelle anschauen etc. für die Schweiz gibt es auch noch eine detaillierte Datenquelle.

        • Der Ländervergleich Todesfallvergleich im Verhältnis zur Bevölkerung

        • Flacht sich die Kurve ab?

 

      • Bestätigte tägliche Todesfälle mit dreitägig rollendem Durchschnitt (meines Erachtens eine der aussagekräftigsten Kennzahlen, da relativ klar und nicht über tägliche Meldezahlen zu stark verzerrt).

      • Tote im Verhältnis zur Bevölkerung (hier Schweiz)

    • Bestätigte Todesfälle (Achtung: in China, aber auch bspw. Schweden werden wohl zuwenige gemeldet).

  • Todesfallraten (Verhältnis zu bestätigten Fällen)
  • Dies sind nur die offiziell gemeldeten/getesteten Fälle und sind wesentlich unter den wahren Fallzahlen.

        • Todesrate im Verhältnis zu postiv gestesteten

    • Testrate in Korrelation zum Alter der Verstorbenen

    • Die Altersstruktur der Länder

    • Medizinische Versorgung anhand der Bettenanzahl

    • Ärzte pro Einwohner

Es ist schwierig in der COVID-19-Krise einen Überblick über die Daten zu haben und zu bestimmen, welches die relevanten sind.

 

Herzlichen Dank an die Autoren/Quelle für diese Einsichten/Illustrierungen

Max Roser, Hannah Ritchie and Esteban Ortiz-Ospina (2020) - "Coronavirus Disease (COVID-19) – Statistics and Research"

 


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR

Martin Signer

2 months ago

Die epidemologische Kurve anhand bestätigter Fälle

Es ist schwierig in der COVID-19-Krise einen Überblick über die Daten zu haben.

Hier eine interaktive Graphik

 


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR

Martin Signer

2 months ago

Vergleich auf der epidemologischen Entwicklung der DACH-Länder Südeuropa und der USA mit bestätigten Toten

Es ist schwierig in der COVID-19-Krise einen Überblick über die Daten zu haben.

Hier eine interaktive, eindrückliche visualisierende Karte zum Schauen, wo wir auf der epidemologischen Kurve sindQuelle: https://ourworldindata.org/coronavirus


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR

Martin Signer

2 months ago

Szenariogenerierungstechnik mit Momentanpassungstransformationen für die stochastische Modellierung der COVID-19-Pandemie

Ich hatte meine Lizenziatsarbeit in Quantitative Finance zum Thema der stochastischen Modellierung mittels Szenariogenerierungstechnik mit Momentanpassungstransformationen am OperationsResearch Institut der Universität Zürich geschrieben (mit entsprechenden Simulationen).

Für die Modellierung/Simulation der verschiedenen stochastischen  Szenarien der epidemologischenKurve des COVID1Verlaufs könnte dies eine hilfreiche Quelle sein, weswegen ich sie hier gerne kostenlos zur Verfügung stelle. Der Quellcode der Simulationen müsste ich suchen, wäre jedoch wohl auch vorhanden. Auf https://www.smartmoneymatch.com/de/in-den-medien werde ich in den nächsten Tagen noch mehr Literatur zur Verfügung stellen.


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR

Martin Signer

2 months ago

What are the appropriate assessment figures for the COVID-19 outbreak?

As I mentioned in this article (in German) the general news outlet reporting of COVID-19 statistics has some short-comings. 

Valuable data are available on worldometer's coronavirus cases like e.g. by underlying factors

Good illustrations/examples are also on Ourworldindata

Also, a good data source is from Johns Hopkins University.

By the end, it's though still a lot of speculation and unreliable data

The main points are:

  • Generally, only confirmed cases are reported.
  • There's no proper track of recoveries
  • Doubt regarding the reliability of the official Chinese figures regarding the infection rate/death toll. Sources like the Business Insider speculate about 15 until 40 times underreporting of the death toll.
  • This BBC article stresses the test/infection ratio of cases.

Here also an interesting video regarding visualization issues

Helpful are also simulation studies.


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR

Martin Signer

2 months ago

Methodische Mängel der Datenerhebung beim Testen und Behandeln von COVID-19

Da COVID-19 eine relativ neue Infektionskrankheit ist, fehlen leider die relevanten Daten (hier mit interaktiven Charts).

Testen

Beim Testen/Reporting der Fallzahlen bestehen insbesondere folgende methodische Schwierigkeiten (es soll hier nicht unerwähnt bleiben, dass das Testen auch eine Ressourcenfrage ist):

  • Es werden nur positiv getestete gemeldet. Interessant wäre hier insbesondere auch das Verhältnis von positiv/negativ-Getesteten
  • Es gibt keine Angaben über Angaben wie Alter, Geschlecht, Symptome, Komorbiditäten der Getesteten.
  • Allgemein sieht man nicht das Follow-up (bspw. nach 14-Tagen) von postitiv Getesteten.
  • Es sind wenig Daten über Stichprobentestings für verschiedene Bevölkerungsgruppen vorhanden.

 

Therapeutisch/Ansteckungsverhinderung

Therapeutische Behandlung in den verschiedenen Phasen

  • Die erste Abwehr der Ansteckungsverhinderung ist mit dem Social-Distancing, Hygiene, etc. wohl inzwischen einigermassen gut abgedeckt (wobei wohl Masken auch hilfreich wären, dies scheint jedoch ein Resourcenproblem zu sein).
  • Bei schweren Verläufen mit den Intensivabteilungen scheint man auch viel zu investieren in Beatmungsgeräte, Medikamentenbeschaffung etc.
  • Bei milden Symptomen (postitiv getestet) - welche sich verschlimmern können - bis zur Hospitalisierung schein man jedoch mit der Aufforderung zur Selbstquarantäne möglicherweise zu lange zuzuwarten, bis sich der Zustand der Patienten (potentiell) verschlechtert (und sie dann in die Intensivabteilung kommen). Hier wäre es meiner Ansicht nach sehr wichtig, entsprechende Daten systematisch zu sammeln, testen und auszuwerten.

Ethische Überlegungen

Hier noch Simulationen wie sich die Pandemie ausbreiten könnte, abhängig von den getroffenen Massnahmen und Annahmen

 


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR

Martin Signer

2 months ago

Mögliche Hilfe der Naturheilkunde gegen COVID-19

Wichtig: Dieser Artikel ist keine therapeutische Empfehlung sondern dient als reines Gedankenspiel des Autors. Es soll daraus auch keine therapeutische Empfehlung abgeleitet werden, insbesondere nicht für ältere Personen, Personen mit Vorerkrankungen und Personen mit schweren Symptomen.

Für therapeutische Empfehlungen ist der Rat einer staatlich anerkannten, qualifizierten Fachperson zu konsultieren.

Meines Erachtens ist frühes energisches Separieren die derzeit erfolgreichste Strategie.

Auch eine mögliche frühzeitige Behandlung könnte Linderung geben, wie hier einige Fälle dokumentiert sind.

Bspw.:

vor dem Schauen des untenstehendem Video soll bitte klar geschaut vor Banalisierungen gewarnt werden.

Während ich die Meinung vertrete, dass einige Sachen von Dr. Bircher (gefährlich) verharmlost werden und frühes energisches Separieren unbedingt notwendig ist um die Ausbreitung einzuschränken, scheinen gewisse Tipps gut zu sein wie untenstehendes Video zeigt.:

Die einzelnen Tipps zum eigenen Verhalten zur Stärkung des Immunsystems mögen sinnvoll sein, die Gesamtanalyse scheint falsch!

 

Die Kritik an den geforderten Versuchtsanordnungen (randomisiert/plazebokontrolliert) etc., damit Medikamente eingesetzt werden können, scheinen nicht vollkommen aus der Luft gegriffen zu sein.

Hier noch etwas bzgl. Vitamin D

Disclaimer: Ich liebe Birchermüesli :-)


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR

Martin Signer

2 months ago

Die Subventionierung der Banken durch die Bundesmassnahmen mit bis zu 750000000 CHF

Article about Die Subventionierung der Banken durch die Bundesmassnahmen mit bis zu 750000000 CHF

Während der Ueli Maurer soviel gelobt wird, hier einige Kritiken:

1. Kredite an Start-ups und andere Unternehmen mit wenig Umsatz finden generell nicht statt, da die Kreditsumme auf 10% des Umsatzes beschränkt ist.

2. Die Banken werden folgendermassen subventioniert werden:

  • Sie bekommen für eine risikofreie Anleihe (die Kredite werden vom Bund garantiert) 0% Zins.
  • Der Marktzins ist - 0.75% (d. h. der Leitzins der Nationalbank).

Dies gibt eine Zinsdifferenz von 0.75%. Dies ist für die Banken - welche die Kredite während der Coronaviruskrise vergeben - eine Arbitrage.

D. h. falls das Kreditvolumen von 20 Mrd. CHF während 5 Jahren ausgeschöpft wird, ergibt dies

ca. 20 Mrd. CHF x 5 Jahre x 0.75%/Jahr = 750000000 CHF Subventionen.

 

Auch sonst haben die Schweizer Behörden bspw. mit der verschleppten Reaktion - spätestens am 23. Februar waren die Fakten klar - bis am 13. März eine schlechte Figur gemacht.

 


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR

Martin Signer

2 months ago

Die einzige Waffe gegen COVID-19 ist der gesunde Menschenverstand jedoch sind die meisten Menschen unbewaffnet

Leider gibt es immer noch etliche Personen, welche die Gefährlichkeit der COVID-19-Pandemie unterschätzen. Hierzu jemand der sich verdienterweise die Mühe gemacht hat, dies zu widerlegen

Andere suchen falsche Lösungen.

Panik ist ein schlechter Berater, aber ebenfalls Ignoranz wie bspw. lange Zeit in der Schweiz

oder immer noch in Schweden.

Ein Grund könnte untenstehend sein


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR

Martin Signer

2 months ago

Why understanding of chemistry might be helpful

It's a very good incentive for learning biochemistry.


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR

Martin Signer

2 months ago

Alter Schwede wohl bald ein Ausdruck aus der Vergangenheit

Article about Alter Schwede wohl bald ein Ausdruck aus der Vergangenheit

Schweden scheint noch extremer als andere Länder - bspw. brauchte die Schweiz nach dem 23. Februar volle drei Wochen für griffige Massnahmen - lernresistent zu sein.

Nachdem es sogar in Grossbritannien selbst bei Boris Johnson und in den USA bei Donald Trump angekommen ist - und beide scheinen nicht die hellsten Kerze auf der Torte zu sein - dass der COVID-19 Virus extrem gefährlich ist und "Business as Usual" nicht die richtige Strategie ist, scheinen die schwedischen Politiker den Plan des Selbstgenozid für die Zukunft zu haben:

"Alter Schwede"? Das gab es bei uns früher.


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR
MartinSigner
6 days ago

Katastrophe mit Ansage https://www.20min.ch/story/schweden-verzeichnet-die-hoechste-todesrate-seit-jahrzehnten-651686442039

Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR

Martin Signer

2 months ago

Kirchglockenlärm in der Nacht und am frühen morgen tötet

Der Lärm der Kirchglocken stört erwiesenermassen den Schlaf.

Wie in diesem Artikel

klar gezeigt wird, vermindert der Schlafentzug - wie bspw. durch den Kirchglockenlärm v.a. in der Nacht - die Widerstandsfähigkeit des Immunsystems und wird daher - zusätzlich zur drei Wochen verspäteten Antwort der Schweizer Behörden zur COVID-19-Pandemie - wieder zu zusätzlichen unnötigen Toten durch die Kirche in der Schweiz führen. 


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR

Martin Signer

2 months ago

Video example article with COVID-19 update


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR

Martin Signer

2 months ago

Swiss Life mit starker Solvenz

Swiss Life mit starker Solvenz

 
  • Die Kapitalisierung der Gruppe bleibt auch nach den Verwerfungen an den Kapitalmärkten stark: Der SST liegt aktuell bei rund 175% und damit im oberen Drittel des Zielbereichs von 140 bis 190%.
     
  • Wie alle anderen grossen börsenkotierten Banken und Versicherungen in der SchweizwirdSwiss Life ihr Aktienrückkaufsprogramm aussetzen und vorerst keine Aktien mehr zurückkaufen.
     
  • Wie bereits kommuniziert schlägt der Verwaltungsrat der Generalversammlung für das Geschäftsjahr 2019 eine Dividende von CHF 20 pro Aktie vor. Die Generalversammlung findet ohne physische Teilnahme von Aktionären wie geplant am 28. April 2020 statt.
 

Trotz der jüngsten Verwerfungen an den Finanzmärkten bleibt die Solvenz von Swiss Life stark. Swiss Life ist als Gruppe dem streng kalibrierten Swiss Solvency Test (SST) unterstellt. Per 1. Januar 2020 ging die Swiss Life-Gruppe von einer SST-Quote von gut 200% (Vorjahr: 185%) aus. Aktuell liegt die SST-Quote bei rund 175% und damit im oberen Drittel des Zielbandes von 140 bis 190%.

 

Die Risiken des Kapitalmarkts managt Swiss Life im Rahmen ihrer kontinuierlichen Asset-Liability-Prozesse. Swiss Life verfügt über ein gut diversifiziertes Anlageportfolio mit hoher Bonität. Das Aktienportfolio ist abgesichert, die Netto-Aktienquote betrug per 31. Dezember 2019 4,1% und ist seither auf rund 2% halbiert worden.

 

Bezüglich der versicherten Risiken hat Swiss Life ein ausgewogenes Portfolio von Sterblichkeits- und Langlebigkeitsrisiken. Entsprechend sind die Verlustrisiken daraus für Swiss Life überschaubar. Die grössten Effekte sind für Swiss Life über die Auswirkungen an den Finanzmärkten spürbar.

 

Swiss Life-CEO Patrick Frost sagt: «Unterstützt durch unser diszipliniertes Asset-Liability-Management bleibt unsere Solvenz auch nach den jüngsten Verwerfungen im Kapitalmarkt stark. Wie alle anderen grossen börsenkotierten Banken und Versicherungen in der Schweiz werden wir unser Aktienrückkaufsprogramm aussetzen und vorerst keine Aktien mehr zurückkaufen.»

 

Die Generalversammlung findet ohne physische Teilnahme der Aktionäre wie geplant am 28. April 2020 statt. Wie bereits kommuniziert schlägt der Verwaltungsrat der Generalversammlung für das Geschäftsjahr 2019 eine Dividende von CHF 20 pro Aktie vor.


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR

Martin Signer

2 months ago

Skanska sells office building in Warsawfor EUR 98m

Skanska has sold Generation Park Z office building in Warsaw to Deka Immobilien, one of Europe’s leading real estate investment managers. This is the buyer’s fourth acquisition with Skanska in Central and Eastern Europe.

Generation Park Z is part of the Generation Park office complex located in the heart of Warsaw. The three-building complex offers ca. 87,000 sqm and benefits from very good transportation options including the second metro line, trams, and buses in the immediate proximity to the Daszyńskiego Roundabout. Generation Park Z is fully leased to Vistra and Crido, among others. The property comprises a total leasable area of approx. 19,000 sqm and 110 underground parking places for cars, as well as 102 for bikes. It offers a convenient infrastructure for cyclists and runners, including showers and changing rooms.

 

“Skanska has been an active player in the Warsaw office market for years. Generation Park Z is located in the most desirable and fastest growing Warsaw city center destination in recent years. The demand for prime office buildings in this location is extremely high, that’s why we are happy to meet the needs of investors and tenants by delivering our innovative and futureproof workplaces there. We are pleased that Deka has once again chosen one of our buildings,” says Adrian Karczewicz, Head of Divestments at Skanska commercial development business unit in the CEE.
 

The demand for new offices in the capital city of Poland remains very high and drives developer activity. In 2019, seventeen new buildings were delivered with a total volume of 162,000 sqm and Generation Park Z was one of the three largest office developments among them, according to JLL.

 

Obraz zawierający budynek, zewnętrzne, duży, siedzi Opis wygenerowany automatycznie


Skanska focuses on delivering sustainable and human-centric projects that are environmentally friendly and support the tenants’ health and wellbeing. Common areas in Generation Park Z consist of many elements such as a tree in the main lobby or a mural inside the garage entrance. The property offers amenities – restaurants and coffee shops. It also has a terrace on the 13th floor with a lot of greenery, which provides an excellent view on the neighborhood and is a great place to relax, work, organize company events or fitness activities. Generation Park Z provides easy access to the office complex patio, which includes green areas with a garden café, meeting points or bike infrastructure. The pavement on the patio and around the building is an innovative “green concrete”, a unique self-cleaning product that also cleans the air of toxic compounds from car exhausts. 
 

The building is equipped with an integrated building operating system – Connected by Skanska – which facilitates daily office management. The system will enable users to move around the building using their smartphone instead of traditional access cards. It will also provide a virtual reception. The building will feature a parking system that will recognize license plates and allocate available spaces.

 

Generation Park Z has been LEED Platinum pre-certified and is applying for WELL certification. It will also apply for the Building without Barriers certificate, which proves that the building is friendly and adapted to the needs of people with disabilities and with children. 

 

Skanska

 

Skanska is one of the leading development and construction companies in Europe. Outside the Nordics, the company has operations in building construction and civil engineering in Poland, Czech Republic & Slovakia, and the UK. Skanska develops commercial properties in selected home markets in Poland, Czech Republic, Romania, and Hungary, while residential development is active in Poland, Czech Republic and in the UK with the BoKlok concept. In 2019, Skanska had sales of SEK 33 billion and about 11,700 employees in its European operations outside the Nordics. 


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR

Martin Signer

2 months ago

Mehr Sicherheit durch reformiertes Wohngeld

Verschlanken, digitalisieren, vertrauen: Mehr Sicherheit durch reformiertes Wohngeld!

 

„Einkommensverluste als Folge der Corona-Krise dürfen nicht dazu führen, dass Mieter die Wohnkosten nicht mehr aufbringen können. Deshalb sollten betroffene Mieter schneller und unbürokratisch Wohngeld erhalten. Das gilt auch für die Gewährung eines Lastenzuschusses für Selbstnutzer, die in finanzielle Not geraten sind.  Was wir jetzt brauchen, ist eine Reform des Wohngeld-Antrags unter dem Dreiklang „Verschlanken – digitalisieren – vertrauen“! So können wir ein Stück Sicherheit in unsicheren Zeiten schaffen“, sagte Andreas Ibel, Präsident des BFW Bundesverbandes, heute in Berlin.

Verschlanken und digitalisieren

„Hierzu braucht es keine neuen, sondern die Stärkung und Anpassung von bewährten, zielgenauen Instrumenten“, so Ibel weiter. Der BFW-Präsident verwies darauf, dass in der Vergangenheit nur ein kleiner Teil der Wohngeld-Berechtigten einen Antrag gestellt hat. „Vielen Menschen mit geringem Einkommen oder vorübergehenden Einkommensverlusten ist gar nicht bewusst, dass sie Anspruch auf einen Miet-Zuschuss haben. Das Wohngeld hatte schon immer ein Bekanntheitsproblem. Das muss jetzt mit großer Entschlossenheit beseitigt werden.  Zudem muss es jetzt darum gehen, die Zugangshürden zu senken. Der Antrag darf bei akutem Hilfsbedarf nicht zum langwierigen Behördenlauf ins Bürgeramt, sondern muss verschlankt und digitalisiert werden.“

„Vertrauen“ – erst zahlen, dann prüfen

Ibel weiter: „Was wir zudem brauchen, ist eine Umkehr der Beweislast beim Wohngeld-Antrag. Menschen, die Einkommensverluste erleiden, müssen rasch und unbürokratisch einen Vorschuss ausgezahlt bekommen. Die Vermögensprüfung kann dann in einem zweiten Schritt erfolgen!“


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR

Martin Signer

2 months ago

Mitigating the current crisis with online tools and digitization

 


Due to the COVID19 outbreak, it looks like that because of the social distancing recommended in the hope of slowing down the spread of the virus and flattening the pandemic curve most professionals in the investment industry will be working from their home office for the coming weeks.

While first, and foremost the goal should be to stay healthy, here are some ideas about how to digitize the working process and how SmartMoneyMatch can help.

Please note: All offers are at no charge, we can help to provide more visibility.

Should you not have an account yet, please:

As we also have the biggest event calendar dedicated to the investment industry—many of the events in the coming weeks will obviously have to be re-scheduled—we also encourage you to offer some webinars or e-conferences.

You can also list post banners. Should you be interested in a mail campaign, please contact me directly.

I hope you stay healthy and well over this challenging period.


Martin Signer
Managing Director

P.S. Unfortunately, authorities throughout Europe and North America have failed to respond in a timely way to the known facts. For example, we urged the Swiss authorities on February 23rd to take decisive measures that took an additional three weeks until they were implemented.
This delay will, unfortunately, cost many lives and cause human tragedies.
We especially appreciate it if you support people in need in these times.

Be seen. Be heard. Be remembered.

We offer visibility to our network of 450,000+ people:


To find out more, get in touch with
Martin.Signer@SmartMoneyMatch.com +41 43 333 10 38.

 

 


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR

Martin Signer

2 months ago

INVIBES a augmaunté le capital

INVIBES ADVERTISING annonce le succès de la seconde tranche de son augmentation de capital d’un montant total de 2,5 M€

 

• Placement privé réalisé auprès de GENERIS CAPITAL PARTNERS pour 1,5 M€ en complément de la première tranche de 1,0 M€ levée en octobre 2019

 

• Prix unitaire moyen pondéré de 8,00 € par action, représentant une prime de 40% par rapport au dernier cours 

 

Paris, 18 mars 2020 - INVIBES ADVERTISING, société technologique du secteur de la publicité digitale, annonce aujourd’hui avoir réalisé avec succès la seconde tranche de l’augmentation de capital réservée aux fonds gérés par GENERIS CAPITAL PARTNERS, pour un montant total de 2,5 M€.

 

Cette augmentation de capital, réalisée avec suppression du droit préférentiel de souscription dans le cadre d’un placement privé, souscrite entièrement par GENERIS CAPITAL PARTNERS, s’est décomposée en deux tranches et un complément :

 

- une première tranche réalisée en novembre 2019 d’un montant de 1,0 M€, prime d’émission comprise, par émission d’actions ordinaires représentant 181.818 actions nouvelles, avec suppression du droit préférentiel de souscription, au prix de 5,50 € par action ;

 

- une deuxième tranche réalisée le 16 mars 2020 d’un montant de 1,0 M€, prime d’émission comprise. Conditionnée à la réalisation d’objectifs de chiffre d’affaires et d’EBITDA en 2019, cette seconde tranche, compte tenu de l’atteinte de ces objectifs sur l’exercice, s’est ainsi traduite par l’émission de 68.166 actions nouvelles, avec suppression du droit préférentiel de souscription, au prix de 14,67 € par action ;

 

- un complément d’augmentation de capital d’un montant de 500 K€, prime d’émission comprise, a été décidé par les parties, portant sur l’émission de 62.488 actions nouvelles, avec suppression du droit préférentiel de souscription, au prix de 8,00 € par action, correspondant au prix unitaire moyen pondéré par action des deux premières tranches.

 

Au total, l’augmentation de capital, réalisée pour un montant total de 2,5 M€, prime d’émission comprise, a donné lieu à l’émission de 312.472 actions nouvelles au prix unitaire moyen pondéré de 8,00 € par action. 


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR

Martin Signer

2 months ago

Invibes successfully raised capital

INVIBES ADVERTISING announces success of second tranche of €2.5m capital increase

 

• Private placement of €1.5m issued to GENERIS CAPITAL PARTNERS in addition to first tranche of €1.0m raised in October 2019

 

• Weighted average unit price of €8.00 per share, implying a 40% premium on the most recent share price

 

London, 18 March, 2020 - INVIBES ADVERTISING, a tech firm specialising in digital advertising, today announced the success of the second tranche of its €2.5m capital increase reserved for the investment funds managed by GENERIS CAPITAL PARTNERS.

 

The capital increase was issued, without pre-emptive subscription rights, under a private placement to which GENERIS CAPITAL PARTNERS fully subscribed. It consisted of two tranches and a top-up placement:

 

- a first tranche, in the amount of €1.0m including the issue premium, was completed in November 2019, resulting in the issue of 181,818 new ordinary shares without pre-emptive subscription rights, priced at €5.50 per share;

 

- a second tranche, in the amount of €1.0m including the issue premium, was completed on 16 March 2020. The transaction was contingent upon revenue and EBITDA targets for 2019 which were effectively met, resulting in the issue of 68,166 new shares, without pre-emptive subscription rights, at a unit price of €14.67;

 

- a top-up placement of €500k, including the issue premium, was agreed by the parties, resulting in the issue of 62,488 new shares, without pre-emptive subscription rights, at a price of €8.00 per share, which is the weighted average unit price per share of the first two tranches.

 

Overall, the capital increase raised a total of €2.5m, including the issue premium, and resulted in the issue of 312,472 new shares at an average weighted price of €8.00 per share. 


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR

Martin Signer

2 months ago

Crypto Broker AG lanciert Limit-Orders

CRYPTO BROKER AG LANCIERT ALS ERSTER ANBIETER IN EUROPA 24/7-LIMIT-ORDERS AUF EINER PROFESSIONELLEN KRYPTO-HANDELSPLATTFORM

Die Crypto Broker AG bringt Limit-Order-Funktionalitäten auf ihre Crypto Asset Trader (CAT) Plattform. Diese Funktion dient als eine willkommene Unterstützung des Risikomanagements im Hinblick auf die steigende Volatilität an den Krypto sowie traditionellen Märkten in Verbindung mit dem Coronavirus. Die Crypto Broker AG entlastet damit institutionelle und professionelle Anleger von der ständigen Überwachung der Live-Kurse von mehreren Börsen und Brokern weltweit, wodurch sie sich auf ihre Kernkompetenzen konzentrieren können. Als erster professioneller Krypto-Broker in Europa, der diese Funktion rund um die Uhr zur Verfügung stellt, ist die Crypto Broker AG einer der wenigen weltweit, welche einen effizienten Handel, Best-Price-Execution, eine stetig wachsende Bandbreite an Handelspaaren und professionelle Liquidität ermöglichen. Die Limit-Orders sind eine weitere Ergänzung für die marktführende Crypto Broker Infrastruktur.

Die Crypto Broker AG, eine Tochtergesellschaft der Crypto Finance AG, hat die Einführung von automatisierten Limit-Orders für den 24/7 Krypto-Handel bekannt gegeben. Damit ergänzt das Unternehmen ihr marktführendes und professionelles Krypto-Handelsgeschäft auf ihrem Crypto Asset Trader (CAT). Die Crypto Broker AG ist der erste professionelle Krypto-Asset Dienstleister in Europa, der Limit-Orders mit automatisiertem 24/7-Handel anbietet. Das Unternehmen gehört somit zu den wenigen führenden globalen Krypto-Brokern, welche diese Funktion für institutionelle und professionelle Investoren für eine Bandbreite an Krypto-Fiat Handelspaaren anbieten.

Die Limit-Order-Funktionalität der Crypto Broker AG ist ein weiterer Schritt, um die Lücke zwischen der globalen Finanzwelt und dem aufstrebenden Markt für digitale Vermögenswerte zu schliessen. Die erleichterte 24/7 Online-Orderplatzierung für Krypto-Anlagen entlastet die Kunden von der ständigen Überwachung der Live-Preise an mehreren Börsen und Brokern weltweit, so dass sie sich auf ihre Kernkompetenzen konzentrieren können. Ab sofort ist dies für 10 handelbare Krypto-Fiat Paare möglich, wobei weitere Handelspaare noch in diesem Jahr folgen werden. Der Handel mit Limit-Orders war für Kunden über das Crypto Broker Trading Team schon immer möglich. Nun ist diese Funktion bequem und rund um die Uhr auch im Crypto Asset Trader (CAT) verfügbar. Die Crypto Broker AG hat diese Funktionalität zudem ebenfalls direkt über API und das FIX-Protokoll lanciert, was von ihren institutionellen Kunden verwendet und in deren Systemen angeboten wird.

Mit der Dynamik der Krypto-Märkte mithalten: Die Crypto Broker AG macht es möglich mit automatisiertem, sicheren und professionellem 24/7 Krypto-Asset-Trading
Die Crypto Broker AG bietet Ihnen einen professionellen Zugang zum Handel mit Krypto-Assets sowie Liquidität an den weltweit führenden Krypto-Börsen, 24 Stunden am Tag, 7 Tage die Woche und 365 Tage im Jahr. Für Anleger, welche sowohl in Krypto Märkten als auch in etablierten Finanzmärkten aktiv sind, ermöglicht die Crypto Broker AG einen professionellen, sicheren und dauerhaften Zugang zum Krypto-Markt. Durch die Ergänzung fortschrittlicher Order-Typen mit Schweizer Ausführungsqualität ermöglicht die Crypto Broker AG ihren Kunden die Festlegung von Risikolimiten mit Best-Price-Execution sowie professioneller Post-Trade-Abwicklung und Verwahrung. Damit können sich ihre Kunden auf ihre Kernkompetenz in der Vermögensverwaltung, im Portfolio Management oder im Research konzentrieren. Jan Brzezek, CEO und Gründer der Gruppe, kommentiert: «Mit den Limit-Orders, die zu unseren sicheren, rund um die Uhr verfügbaren Handels- und Lagerungsdienstleistungen hinzukommen, macht es die Crypto Broker AG unseren Bank- und Fondskunden leicht, grosse Krypto-Asset-Portfolios zu verwalten.»

Simon Tobler, Head of Trading bei der Crypto Broker AG, kommentiert: «Durch die Erweiterung unseres Angebots um Limit-Orders mit derselben professionellen Präzision, wie sie auf den traditionellen Finanzmärkten zu finden ist, können unsere Kunden den Handel rund um die Uhr bequem abwickeln. Die Crypto Broker AG wird als First Mover in den Digital Asset Märkten weiterhin neue Standards in der automatisierten Handelsinfrastruktur setzen.»

Über die Crypto Broker AG
Die Crypto Broker AG ermöglicht institutionellen und professionellen Anlegern den Zugang zur aufstrebenden Digital Asset Anlagekategorie mit sicheren, liquiden und transparenten Handelsdienstleistungen. Die Crypto Broker AG ist VQF Mitglied und bietet Investoren einen professionellen Zugang zum Krypto-Anlagemarkt. Die Handelsinfrastruktur wurde von einem spezialisierten Team aus Handels-, Krypto- und IT-Experten entwickelt und unterhalten. Die Infrastruktur der Crypto Broker AG ermöglicht den Zugang zu den weltweit führenden Krypto-Börsen über ein proprietäres algorithmisches Auftragsmanagementsystem und bietet sowohl RFQ als auch Streaming-Preise.

Über die Crypto Finance Gruppe
Die Crypto Finance Gruppe bietet professionellen und institutionellen Anlegern Produkte und Dienstleistungen für Krypto-Assets, die sich durch Exzellenz, Qualität und Integrität auszeichnen. Zur Gruppe gehören die Holdinggesellschaft Crypto Finance AG und die drei Tochtergesellschaften: Die Crypto Fund AG, die erste regulierte Vermögensverwalterin für Krypto-Assets, die von der FINMA bewilligt wurde; die Crypto Broker AG, tätig im Trading von Krypto-Assets; und die Crypto Storage AG, die Infrastruktur Dienstleistungen für die sichere Lagerung von Krypto-Assets bereitstellt. Seit ihrem Bestehen wurde die Firma bereits mehrmals ausgezeichnet, unter anderem in der Top 50 Blockchain-Unternehmen des Crypto Valley und der Top 100 Swiss Startups sowie auch als Gewinnerin der «Swiss FinTech Awards 2019».

Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR

Martin Signer

3 months ago

Private Placement Markets in March of 2020 with Strong Deal Activity Despite Worsening Macro Conditions

The Private Placement Markets Complete an Impressive Decade of Growth. Private Placement Market Assets Under Management (AUM) grew by 10 percent in 2019, and by $4 Trillion USD in the past decade, an increase of 170 percent, while the number of active private equity (PE) firms has more than doubled and the number of U.S. sponsor-backed companies has increased by 60 percent. Over that same period, Global Public Market AUM has grown by roughly 100 percent, while the number of US publicly traded companies has stayed roughly flat (but is down nearly 40 percent since 2000).
 
The Fundraising Outlook Remains Favorable. The early prognosis for the remainder of 2020 is for continued strength: by the end of 2019, large firms had announced targets collectively approaching $350 Billion USD, more than at year-end 2018. Further, limited partners (LPs) continue to raise their target allocations to Private Placement Markets. Even at current levels, LPs appear to be under-allocated versus target levels by more than $500 Billion USD in Private Equity alone—as much as the global amount raised for Private Equity in 2019.
 
Some 57% of Private Placement Markets – Market Participants (institutional investors) surveyed by Market Coordinators of the Private Placement Debt & Equity Markets worldwide think the economy has reached a cyclical peak, while 14% think it has already entered a recession. They are also significantly more worried about geopolitical conditions than they were a year earlier. Overall, these concerns about market stability help explain why their No. 1 source of anxiety (70% of respondents) is overheated asset valuations.
 
A growing number of Private Placement Markets – Market Participants (institutional investors) have already taken steps to prepare. Roughly 40% of the Global Investors surveyed have altered their investment strategies, with some assessing recession risks more carefully during due diligence. Others are building more balanced portfolios to emphasize countercyclicality, and most are either accelerating exits or getting more wary of overpaying.
 
Despite the somber macroeconomic outlook from the recent Global Coronavirus Outbreak, Private Placement Markets investing activity is not slow much signs of slowing down. Private Placement Market Investors and Fund Managers currently active in the Debt and Equity Markets have continued to make deals on the Primary Markets, find exits on the Secondary Markets and raise even more capital than ever (though through fewer funds), fueled by enthusiasm from the vastly developing Private Placement Markets.
 

Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR

Martin Signer

3 months ago

Helvetica Swiss Commercial Fund with a Successful Financial Year 2019

Helvetica Swiss Commercial Fund: successful financial year 2019; investment return of 6.3%

 
 
  • Real estate portfolio +47% to CHF 628.9 million
  • Total fund assets +47% to CHF 654.7 million
  • Rental income +58% to CHF 29.3 million
  • Investment return 2019 of 6.3%
  • Distribution of CHF 5.00 per share corresponds to payout yield of 4.06%
  • HSC Fund listed on SIX Swiss Exchange since 11 November 2019

 

Zürich, 16 March 2020 –The Helvetica Swiss Commercial Fund (HSC Fund) reports a very successful financial year 2019. The high-quality real estate portfolio was further diversified through the acquisition of 9 properties and reached a value of CHF 628.9 million by year-end 2019. The investment return in 2019 reached 6.3%. The distribution of CHF 5.00 per share, which will be paid out in April 2020, corresponds to a payout yield of 4.06% with a corresponding payout ratio of 87.6%. 

 

Details to the results for financial year 2019

 

Income statement
Rental income increased by 58% to CHF 29.3 million in the reporting period 2019 (FY 2018: CHF 18.5 million). The occupancy rate as at 31 December 2019 remained stable compared to the previous year and amounted to 94.1% (FY 2018: 94.2%). Net income was increased to CHF 23.0 million (FY 2018: CHF 14.3 million). The divestment of a property in Vevey resulted in a non-recurring profit of CHF 2.3 million. The valuation of the portfolio by Wüest Partner AG, the independent real estate evaluator, led to a non-realised profit of CHF 4.9 million (FY 2018: CHF 3.3 million). Total comprehensive income for the reporting period 2019 rose by 77% to CHF 29.1 million (FY 2018: CHF 16.5 million).  

 

Balance sheet
Total fund assets were CHF 654.7 million as of 31 December 2019 (31.12.2018: CHF 444.9 million). The value of the real estate portfolio was CHF 628.9 million as of year-end 2019 (31.12.2018: CHF 427.1 million). The increase of 47% is due to the acquisition of 9 attractive properties, located in Bischofszell/TG, Ittigen/BE, Lyssach/BE, Rorschach/SG, Thun/BE, Triengen/LU, Villars-sur-Glane/FR and Winterthur/ZH. After deduction of liabilities in the amount of CHF 153.8 million (31.12.2018: CHF 131.4 million) and estimated liquidation taxes of CHF 11.4 million (31.12.2018: CHF 7.7 million), the Net Asset Value increased by 60% to CHF 489.5 million (31.12.2018: CHF 305.7 million). The NAV per share amounted to CHF 112.71 as of 31 December 2019 (31.12.2018: CHF 110.00). The number of shares was increased during 2019 by 1,563,426 to 4,342,851 shares as a result of the capital increases in March and September 2019.

 

Distribution of CHF 5.00 per share
For the financial year ending 31 December 2019, a total amount of CHF 21.7 million will be distributed, representing CHF 5.00 per share and a distribution yield on the share price of 4.06%. The distribution for the financial year 2019 includes a one-off effect from the sale of a property in Vevey of CHF 0.54 per share. The total distribution is thus CHF 1.00 or 25% higher than in the previous year. The payout ratio is 87.6%. Without the one-off effect, the payout ratio is 84.1%. The ex-date is 27 April 2020 and the payout will take place on 29 April 2020.

 

Outlook
The fund management company is convinced about the attractivity of the real estate market Switzerland and plans to further develop the portfolio during 2020 in accordance with the investment strategy. The focus continues to be on properties with value appreciation potential in the most dynamic economic regions in Switzerland. Further capital increases to enable the purchase of additional, attractive properties are also planned in line with the growth strategy.

 

 

KEY FIGURES FINANCIAL YEAR 2019

 

 

 

Key data

 

As of 31.12.2019

As of 31.12.2018

Market value of the properties

CHF

628 944 000

427 121 000

Weighted real discount rate

%

4.01

4.11

Total fund assets

CHF

654 729 403

444 909 081

Net asset value

CHF

489 475 302

305 729 749

Debt financing ratio

%

20.87

28.33

Debt ratio

%

25.24

31.28

Net asset value (NAV) per share

CHF

112.71

110.00

Return on equity (ROE)

%

6.18

5.62

Return on invested capital (ROIC)

%

4.73

4.29

Investment return

%

6.33

5.70

Rental income

CHF

29 292 317

18 539 626

Vacancy rate

%

8.10

7.75

Net income

CHF

23 032 696

14 282 138

Weighted average unexpired lease term (WAULT)

Years

4.40

4.00

Operating profit margin

%

68.60

68.56

Distribution

CHF

5.00 *

4.00

Payout yield

%

4.06

3.64

Payout ratio

%

87.58

77.62

   * including non-recurring effect from sale of property in Vevey

 

 

 

 

 

 

 

 

 

 

              

 

 
 

Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR

Martin Signer

3 months ago

FIABCI Prix d de Excellence Germany 2020 eröffnet

Das Wettbewerbsjahr für den FIABCI Prix d´Excellence Germany 2020 ist eröffnet. Zum siebten Mal zeichnen FIABCI Deutschland und der BFW Bundesverband in dem international renommierten Wettbewerb bundesweit herausragende Projektentwicklungen in den Bereichen Wohnen und Gewerbe aus.

„Der FIABCI Prix d'Excellence Germany ist der erste und bisher einzige bundesweite Wettbewerb, der die Gesamtkonzeption von Projektentwicklungen im Neubau oder Bestand würdigt. Dabei setzen wir vor allem auf integrative Konzepte und innovative, interdisziplinäre Lösungen“, betont FIABCI-Präsident und Jury-Mitglied Michael Heming. Dabei weist Heming auf die Kriterien hin, nach denen die eingereichten Projektentwicklungen bewertet werden: Konzept, Architektur, Logistik, Innovationen, Marketing, Nachhaltigkeit und urbane Integration.

„Durch die Bewertung des Gesamtkonzeptes wollen wir die Synergien zwischen Bauwirtschaft und Baukultur, Politik und Gesellschaft fördern“, sagt Andreas Ibel, Jury-Mitglied und Präsident des BFW Bundesverbandes Freier Immobilien- und Wohnungsunternehmen. „Darauf setzen wir auch bei der Zusammensetzung unserer Jury: Diese bildet mit ihrer individuellen Expertise die ganze Bandbreite der Bewertungskriterien ab, die sich zum Gesamtkonzept einer gelungenen Projektentwicklung zusammenfügen!“

Der 12köpfige Jury gehören neben BFW-Präsident Ibel und FIABCI-Präsident Heming Prof. Dr. Vanessa Borkmann (Forschungsleitung Fraunhofer-Institut für Arbeitswirtschaft und Organisation), Peter Götz (Präsident Advisory Council der GPH), Dr. Regine Jorzick (Hamburg Team), Nicolas Katzung (Immobilien Zeitung), Frank Müller (Vorsitzender BFW Mitteldeutschland), Reiner Nagel (Vorstandsvorsitzender Bundesstiftung Baukultur), Jürgen Michael Schick (Präsident IVD Immobilienverband), Andreas Schulten (Vorstand bulwiengesa AG und gif Gesellschaft für Immobilienwirtschaftliche Forschung), Steffi Strenger (Geschäftsführerin Baustolz München) und Steffen Szeidl (Vorstand Drees & Sommer SE) an. Als Partner für den Projektentwicklungswettbewerb konnten BFW und FIABCI die Bundesstiftung Baukultur und die bulwiengesa AG sowie das Fachmagazin CUBE für eine Medienpartnerschaft gewinnen.

Der FIABCI Prix d´Excellence Germany öffnet den Bewerbern nicht nur in Deutschland Türen: Die Gold-Gewinner in den Bereichen Wohnen und Gewerbe qualifizieren sich für die Teilnahme am internationalen Wettbewerb FIABCI World Prix d´Excellence 2021. „Den Teilnehmern bietet unser Wettbewerb „von der Branche für die Branche“ also nicht nur eine nationale Plattform, sondern auch die Chance auf internationale Präsenz, globalen Erfolg und ein Netzwerk mit Projektentwicklern aus der ganzen Welt“, so FIABCI-Präsident Heming. BFW-Präsident Ibel verweist auf die deutsche Erfolgsbilanz: „In den vergangenen vier Jahren haben unsere deutschen Sieger beim World Prix einmal Gold und viermal Silber gewonnen. Diese Erfolge zeigen, dass deutsche Projektentwicklungen auch im internationalen Vergleich einen ganz hohen Stellenwert haben. Umso gespannter sind wir auf die diesjährigen Bewerbungen!“

Für den FIABCI Prix d´Excellence Germany 2020 sind alle Immobilienprojekte zugelassen, deren Fertigstellung zwischen dem 1. Januar 2018 und 31. Dezember 2020 erfolgt ist. Die Bewerbungen können bis zum 15. Juli eingereicht werden. Die Gewinner des Wettbewerbs werden am 13. November im Rahmen einer feierlichen Gala im Berliner ewerk gekürt.


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR

Martin Signer

3 months ago

Conrad Family Office joins forces with the deVere Group

Having worked increasingly closely with each other in recent months the management teams at Conrad and deVere are delighted to confirm that they have now entered a more formal partnership arrangement.

Established in 2002 by CEO Nigel Green, deVere has grown rapidly to become one of the world’s leading independent financial advisory organisations. Green recognised that with the growth of a truly global economy, more and more people were developing an international outlook and focussing on opportunities abroad. From inception, deVere sought to ensure that its expatriate clients developed, maintained and grew their wealth by providing uniquely tailored and bespoke financial planning.

Nearly twenty years on and the numbers speak for themselves. Today, deVere has well over 80,000 clients in more than 100 different countries and in excess of $10 billion under advice and administration. A multi award winning team, backed up with cutting edge fintech capability, means deVere is truly at the forefront of the advisory industry.

Crucially people, not numbers, remains at the core of both the deVere and Conrad ethos, with both recognising that the success of their clients is key to their own success. Together they combine vast experience assisting overseas investors in a wide range of services, particularly ways in which they can take advantage of London’s once again booming high end property market. Several exciting initiatives are already in the pipeline…

John Clifford, Managing Director, Conrad Family Office commented:
“Over the last year we have forged ever closer links with the excellent team at deVere Group. With a shared passion for delivering only the very best customer service and many synergies, the start of spring feels like a particularly appropriate time to announce this exciting new partnership”

George Burgess, Head of Institutional Real Estate, deVere Group commented:
"From the moment we first met with John and his team it was abundantly clear that their knowledge of the London and wider UK property market was quite simply vast. They are a close-knit team with a family ethos and a shared passion for customer service and we look forward to work more closely with them as the year progresses.”


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR

Martin Signer

3 months ago

BFW hält die Wohngemeinnützigkeit für das falsches Instrument für aktuelle Herausforderungen

„Ein richtiges wohnungspolitisches Instrument zur falschen Zeit ist leider auch nur ein falsches. Damit werden wir die aktuellen Probleme auf dem Wohnungsmarkt nicht lösen können“, so Andreas Ibel, Präsident des BFW Bundesverbandes Freier Immobilien- und Wohnungsunternehmen, zum Gesetzentwurf „Neues Wohngemeinnützigkeitsgesetz – NwohnGG“ der Bundestagsfraktion von Bündnis 90/Grünen. Dieser wird heute im Bundestag diskutiert.

Der Gesetzentwurf hat sich die Schaffung von einer Million Sozialwohnungen mit dauerhaft gebundenen Mieten in den nächsten zehn Jahren zum Ziel gesetzt. Die Kosten des Förderprogramms werden auf drei Milliarden Euro pro Jahr beziffert. Die Wohngemeinnützigkeit, die 1990 aufgrund von Korrupti-onsskandalen und dem Bankrott der gemeinnützigen „Neuen Heimat“ abgeschafft wurde, hatte seine Hochzeit in den 1950er bis 1970er Jahren.

„Bei der damaligen, nachkriegsbedingten Wohnungsnot hatte die Wohngemeinnützigkeit durchaus ihre Berechtigung: Es gab kaum Investoren, aber Bauland im Überfluss und geringe Baukosten. Heute ist die Situation aber genau umgekehrt: Viele Investoren stehen einem immer größerem Baulandmangel und immer mehr Auflagen und Regulierungen im Planungs- und Baurecht gegenüber“, so Ibel und resümiert: „Die Wohngemeinnützigkeit ist deshalb das falsche Instrument für die aktuellen Herausforderungen!“

Ibel verweist zudem auf fehlende Praxistauglichkeit des Gesetzentwurfes: So sollen sich gemeinnützige Wohnbauunternehmen auf Gebiete mit einem angespannten Wohnungsmärkten – also stark nachgefragte Wohngebiete in Ballungszentren -  beschränken. Diese stark verdichteten Lagen weisen nur noch ein geringes bauliches Nachverdichtungspotential auf, das zudem weit-aus höhere, komplexere und somit teurere Anforderungen an die Bebauung stellt. „Die Vorstellung, dass nicht gewinnorientierte Unternehmen in diesen Lagen Neubauwohnungen zu einem Mietpreis mindestens 10 Prozent unter-halb der ortsüblichen Vergleichsmiete anbieten können, ist völlig illusorisch und praxisfern“, so Ibel.

Das Resumée des BFW-Präsidenten: „Soziale Verantwortung und Rendite stehen nicht in einem Widerspruch. Wir müssen die Probleme des heutigen Wohnungsmarktes aber an der Wurzel packen: Damit Bauen und somit auch Wohnen wieder bezahlbare wird, brauchen wir mehr bezahlbares Bauland und weniger bürokratischen Hürden! Zudem muss die BauGB-Novelle schnell in den Bundestag eingebracht werden. Das Gebot der Stunde muss jetzt sein, die Rahmenbedingungen für den Neubau von bezahlbarem Wohnraum mit ganzer Kraft zu fördern!“